



PCT/IB 04 / 03373  
(28.11.04)


REC'D 28 NOV 2004	INVESTOR IN PEOPLE
WIPO The Patent Office	
Concept House Cardiff Road Newport South Wales NP10 8QQ	

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

*P. McHoney*  
13 October 2004

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**Request for grant of a patent**  
See the notes on the back of this form. You can also  
get an explanatory leaflet from the Patent Office to  
help you fill in this form.

**The  
Patent  
Office**

03OCT03 E841735-12 000019  
\_P01/7700 0100-0323102.4

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P035463GB

2. Patent application number

(The Patent Office will fill in this part)

0323102.4

- 2 OCT 2003

3. Full name, address and postcode of the or of  
each applicant (underline all surnames)

CHIRON Srl  
VIA FIORENTINA 1  
53100 SIENA  
ITALY

Patents ADP number (if you know it)

8008812001

If the applicant is a corporate body, give the  
country/state of its incorporation

ITALY

4. Title of the invention

LIQUID VACCINES FOR MULTIPLE MENINGOCOCCAL  
SEROGROUPS

5. Name of your agent (if you have one)

Carpmaels & Ransford

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

43-45 Bloomsbury Square  
London  
WC1A 2RA

Patents ADP number (if you know it)

83001 /

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an  
applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -

Description 38 ✓

Claim(s) 2 ✓

Abstract -

Drawing(s) -

~~+ Sequence listing - 4~~

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) -

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify)

- Sequence listings in duplicate

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Carpmaels & Ransford*  
Carpmaels & Ransford

2nd October 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

CAMERON MARSHALL

020-7242 8692

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## LIQUID VACCINES FOR MULTIPLE MENINGOCOCCAL SEROGROUPS

All documents cited herein are incorporated by reference in their entirety.

### TECHNICAL FIELD

This invention relates to immunisation against bacterial meningitis, and particularly to combined immunisation against bacterial meningitis caused by multiple pathogens.

### BACKGROUND ART

*N.meningitidis* is a non-motile, Gram-negative human pathogen that colonises the pharynx and causes meningitis (and, occasionally, septicaemia in the absence of meningitis). It causes both endemic and epidemic disease. Following the introduction of the conjugate vaccine against *Haemophilus influenzae* type B (Hib), *N.meningitidis* is the major cause of bacterial meningitis in the USA. A third pathogen responsible for bacterial meningitis is *Streptococcus pneumoniae*, but an effective vaccine (PrevNar™ [1]) is now available. Like the Hib vaccine, the pneumococcal vaccine is based on conjugated capsular saccharide antigens.

Based on the organism's capsular polysaccharide, various serogroups of *N.meningitidis* have been identified, including (A, B, C, H, I, K, L, 29E, W135, X, Y & Z. Serogroup A is the pathogen most often implicated in epidemic disease in sub-Saharan Africa. Serogroups B and C are responsible for the vast majority of cases in the United States and in most developed countries. Serogroups W135 and Y are responsible for the rest of the cases in the USA and developed countries. Although the capsular polysaccharide is an effective protective immunogen, each serogroup requires a separate saccharide antigen, and this approach is unsuitable for immunising against serogroup B. Thus the recent success with conjugated saccharide vaccines against serogroup C (Menjugate™ [2], Meningitec™ and NeisVac-C™) has had no impact disease caused by serogroups A, B, W135 or Y; on the contrary, they present a selective pressure towards the emergence of these serogroups as major causes of meningococcal disease.

An injectable tetravalent vaccine of capsular polysaccharides from serogroups A, C, Y & W135 has been known for many years [3,4] and is licensed for human use. The polysaccharides in this vaccine are unconjugated and are present at a 1:1:1:1 weight ratio [5], with 50µg of each purified polysaccharide. Although effective in adolescents and adults, it induces a poor immune response and short duration of protection and cannot be used in infants [e.g. ref. 6]. Furthermore, the vaccines suffer from the disadvantage of requiring reconstitution from lyophilised forms at the time of use.

For serogroup B, a vaccine has proved elusive. Vaccines based on outer-membrane vesicles have been tested [e.g. ref. 7], but protection is typically restricted to the strain used to make the vaccine.

Thus there remains a need for a vaccine which protects against meningococcal serogroups A, C, W135 and Y in children, and also one which does not require reconstitution prior to administration.

Furthermore, there remains a need for a vaccine which broadly protects against serogroup B.

## DISCLOSURE OF THE INVENTION

The invention fulfils all of these various needs, and is based on five separate findings. First, the inventors have found that conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. Second, they have found that this effect is retained when a conjugated capsular saccharide from serogroup A is added. Third, they have found that these conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Fourth, they have found that broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. Finally, they have found that these polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups.

Thus the invention provides an aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is bactericidal against serogroups B, C, W135 and Y of *N.meningitidis*, wherein the composition comprises: (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; and (iv) one or more polypeptide antigens from serogroup B. The aqueous composition may also induce an immune response that is bactericidal against serogroup A of *N.meningitidis*, and may thus further comprise: (v) a conjugated serogroup A capsular saccharide antigen.

Preferred saccharide antigens are oligosaccharides.

### *Serogroups C, W135 and Y*

Techniques for preparing capsular polysaccharides from meningococci have been known for many years, and typically involve a process comprising the steps of polysaccharide precipitation (e.g. using a cationic detergent), ethanol fractionation, cold phenol extraction (to remove protein) and ultracentrifugation (to remove LPS) [e.g. see ref. 8].

A more preferred process [9] involves polysaccharide precipitation followed by solubilisation of the precipitated polysaccharide using a lower alcohol. Precipitation can be achieved using a cationic detergent such as tetrabutylammonium and cetyltrimethylammonium salts (e.g. the bromide salts), or hexadimethrine bromide and myristyltrimethylammonium salts. Cetyltrimethylammonium bromide ('CTAB') is particularly preferred [10]. Solubilisation of the precipitated material can be achieved using a lower alcohol such as methanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, 2-methylpropan-1-ol, 2-methylpropan-2-ol, diols, etc., but ethanol is particularly suitable for solubilising CTAB-polysaccharide complexes. Ethanol may be added to the precipitated polysaccharide to give a final ethanol concentration (based on total content of ethanol and water) of between 50% and 95%.

After re-solubilisation, the polysaccharide may be further treated to remove contaminants. This is particularly important in situations where even minor contamination is not acceptable (e.g. for human vaccine production). This will typically involve one or more steps of filtration e.g. depth filtration, filtration through activated carbon may be used, size filtration and/or ultrafiltration.

Once filtered to remove contaminants, the polysaccharide may be precipitated for further treatment and/or processing. This can be conveniently achieved by exchanging cations (e.g. by the addition of calcium or sodium salts).

After purification, the capsular saccharides are conjugated to carrier proteins as described below.

- 5 As an alternative to purification, capsular saccharides of the present invention may be obtained by total or partial synthesis e.g. Hib synthesis is disclosed in ref. 11, and MenA synthesis in ref. 12.


The saccharide may be chemically modified e.g. it may be O-acetylated or de-O-acetylated. Any such modification preferably takes place before conjugation.

- 10 Saccharides from different serogroups are preferably purified separately, and may then be combined, either before or after conjugation.

### Serogroup A

- 15 Compositions of the invention may include a conjugated serogroup A capsular saccharide antigen. The saccharide can be purified and conjugated in the same way as for serogroups C, W135 and Y (see above), although it is structurally different – whereas the capsules of serogroups C, W135 and Y are based around sialic acid (*N*-acetyl-neuraminic acid, NeuAc), the capsule of serogroup A is based on *N*-acetyl-mannosamine, which is the natural precursor of sialic acid. The serogroup A saccharide is particularly susceptible to hydrolysis, and its instability in aqueous media means that (a) the immunogenicity of liquid vaccines against serogroup A declines over time, and (b) quality control is more difficult, due to release of saccharide hydrolysis products into the vaccine.

- 20 Native MenA capsular saccharide is a homopolymer of ( $\alpha 1 \rightarrow 6$ )-linked *N*-acetyl-D-mannosamine-1-phosphate, with partial O-acetylation at C3 and C4. The principal glycosidic bond is a 1-6 phosphodiester bond involving the hemiacetal group of C1 and the alcohol group of C6 of the D-mannosamine. The average chain length is 93 monomers. It has the following formula:



The inventors have prepared a modified saccharide antigen which retains the immunogenic activity of the native serogroup A saccharide but which is much more stable in water. Hydroxyl groups attached at carbons 3 and 4 of the monosaccharide units are replaced by a blocking group [ref. 13].

The number of monosaccharide units having blocking groups in place of hydroxyls can vary. For example, all or substantially all the monosaccharide units may have blocking groups. Alternatively, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the monosaccharide units may have blocking groups. At least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 monosaccharide units may have blocking groups.

Likewise, the number of blocking groups on a monosaccharide unit may vary. For example, the number of blocking groups on any particular monosaccharide unit may be 1 or 2.

The terminal monosaccharide unit may or may not have a blocking group instead of its native hydroxyl. It is preferred to retain a free anomeric hydroxyl group on a terminal monosaccharide unit in order to provide a handle for further reactions (*e.g.* conjugation). Anomeric hydroxyl groups can be converted to amino groups ( $-\text{NH}_2$  or  $-\text{NH-E}$ , where E is a nitrogen protecting group) by reductive amination (using, for example,  $\text{NaBH}_3\text{CN}/\text{NH}_4\text{Cl}$ ), and can then be regenerated after other hydroxyl groups have been converted to blocking groups.

Blocking groups to replace hydroxyl groups may be directly accessible via a derivatizing reaction of the hydroxyl group *i.e.* by replacing the hydrogen atom of the hydroxyl group with another group. Suitable derivatives of hydroxyl groups which act as blocking groups are, for example, carbamates, sulfonates, carbonates, esters, ethers (*e.g.* silyl ethers or alkyl ethers) and acetals. Some specific examples of such blocking groups are allyl, Aloc, benzyl, BOM, *t*-butyl, trityl, TBS, TBDPS, TES, TMS, TIPS, PMB, MEM, MOM, MTM, THP, *etc.* Other blocking groups that are not directly accessible and which completely replace the hydroxyl group include  $\text{C}_{1-12}$  alkyl,  $\text{C}_{3-12}$  alkyl,  $\text{C}_{5-12}$  aryl,  $\text{C}_{5-12}$  aryl- $\text{C}_{1-6}$  alkyl,  $\text{NR}^1\text{R}^2$  ( $\text{R}^1$  and  $\text{R}^2$  are defined in the following paragraph), H, F, Cl, Br,  $\text{CO}_2\text{H}$ ,  $\text{CO}_2(\text{C}_{1-6}$  alkyl), CN,  $\text{CF}_3$ ,  $\text{CCl}_3$ , *etc.*

Preferred blocking groups are of the formula:  $-\text{O-X-Y}$  or  $-\text{OR}^3$  wherein: X is C(O), S(O) or  $\text{SO}_2$ ; Y is  $\text{C}_{1-12}$  alkyl,  $\text{C}_{1-12}$  alkoxy,  $\text{C}_{3-12}$  cycloalkyl,  $\text{C}_{5-12}$  aryl or  $\text{C}_{5-12}$  aryl- $\text{C}_{1-6}$  alkyl, each of which may optionally be substituted with 1, 2 or 3 groups independently selected from F, Cl, Br,  $\text{CO}_2\text{H}$ ,  $\text{CO}_2(\text{C}_{1-6}$  alkyl), CN,  $\text{CF}_3$  or  $\text{CCl}_3$ ; or Y is  $\text{NR}^1\text{R}^2$ ;  $\text{R}^1$  and  $\text{R}^2$  are independently selected from H,  $\text{C}_{1-12}$  alkyl,  $\text{C}_{3-12}$  cycloalkyl,  $\text{C}_{5-12}$  aryl,  $\text{C}_{5-12}$  aryl- $\text{C}_{1-6}$  alkyl; or  $\text{R}^1$  and  $\text{R}^2$  may be joined to form a  $\text{C}_{3-12}$  saturated heterocyclic group;  $\text{R}^3$  is  $\text{C}_{1-12}$  alkyl or  $\text{C}_{3-12}$  cycloalkyl, each of which may optionally be substituted with 1, 2 or 3 groups independently selected from F, Cl, Br,  $\text{CO}_2(\text{C}_{1-6}$  alkyl), CN,  $\text{CF}_3$  or  $\text{CCl}_3$ ; or  $\text{R}^3$  is  $\text{C}_{5-12}$  aryl or  $\text{C}_{5-12}$  aryl- $\text{C}_{1-6}$  alkyl, each of which may optionally be substituted with 1, 2, 3, 4 or 5 groups selected from F, Cl, Br,  $\text{CO}_2\text{H}$ ,  $\text{CO}_2(\text{C}_{1-6}$  alkyl), CN,  $\text{CF}_3$  or  $\text{CCl}_3$ . When  $\text{R}^3$  is  $\text{C}_{1-12}$  alkyl or  $\text{C}_{3-12}$  cycloalkyl, it is typically substituted with 1, 2 or 3 groups as defined above. When  $\text{R}^1$  and  $\text{R}^2$  are joined to form a  $\text{C}_{3-12}$  saturated heterocyclic group, it is meant that  $\text{R}^1$  and  $\text{R}^2$  together with the nitrogen atom form a saturated heterocyclic group containing any number of carbon atoms between 3 and 12 (*e.g.*  $\text{C}_3$ ,  $\text{C}_4$ ,  $\text{C}_5$ ,  $\text{C}_6$ ,  $\text{C}_7$ ,  $\text{C}_8$ ,  $\text{C}_9$ ,  $\text{C}_{10}$ ,  $\text{C}_{11}$ ,  $\text{C}_{12}$ ). The heterocyclic group may contain 1 or 2

heteroatoms (such as N, O or S) other than the nitrogen atom. Examples of C<sub>3-12</sub> saturated heterocyclic groups are pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, imidazolidinyl, azetidiny and aziridinyl.

Blocking groups -O-X-Y and -OR<sup>3</sup> can be prepared from -OH groups by standard derivatizing procedures, such as reaction of the hydroxyl group with an acyl halide, alkyl halide, sulfonyl halide, etc. Hence, the oxygen atom in -O-X-Y is preferably the oxygen atom of the hydroxyl group, while the -X-Y group in -O-X-Y preferably replaces the hydrogen atom of the hydroxyl group.


Alternatively, the blocking groups may be accessible via a substitution reaction, such as a Mitsunobu-type substitution. These and other methods of preparing blocking groups from hydroxyl groups are well known.

More preferably, the blocking group is -OC(O)CF<sub>3</sub> [14], or a carbamate group -OC(O)NR<sup>1</sup>R<sup>2</sup>, where R<sup>1</sup> and R<sup>2</sup> are independently selected from C<sub>1-6</sub> alkyl. More preferably, R<sup>1</sup> and R<sup>2</sup> are both methyl *i.e.* the blocking group is -OC(O)NMe<sub>2</sub>. Carbamate blocking groups have a stabilizing effect on the glycosidic bond and may be prepared under mild conditions.

Preferred modified MenA saccharides contain *n* monosaccharide units, where at least *h*% of the monosaccharide units do not have -OH groups at both of positions 3 and 4. The value of *h* is 24 or more (*e.g.* 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99 or 100) and is preferably 50 or more. The absent -OH groups are preferably blocking groups as defined above.

Other preferred modified MenA saccharides comprise monosaccharide units, wherein at least *s* of the monosaccharide units do not have -OH at the 3 position and do not have -OH at the 4 position. The value of *s* is at least 1 (*e.g.* 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90). The absent -OH groups are preferably blocking groups as defined above.

Suitable modified MenA saccharides for use with the invention have the formula:







wherein

$n$  is an integer from 1 to 100 (preferably an integer from 5 to 25, more preferably 15-25);

$T$  is of the formula (A) or (B):



(A)



(B)

- 5 each Z group is independently selected from OH or a blocking group as defined above; and each Q group is independently selected from OH or a blocking group as defined above; Y is selected from OH or a blocking group as defined above; E is H or a nitrogen protecting group; and wherein more than about 7% (*e.g.* 8%, 9%, 10% or more) of the Q groups are blocking groups.
- 10 Each of the  $n+2$  Z groups may be the same or different from each other. Likewise, each of the  $n+2$  Q groups may be the same or different from each other. All the Z groups may be OH. Alternatively, at least 10%, 20, 30%, 40%, 50% or 60% of the Z groups may be OAc. Preferably, about 70% of the Z groups are OAc, with the remainder of the Z groups being OH or blocking groups as defined above. At least about 7% of Q groups are blocking groups. Preferably, at least 10%, 20%, 30%, 40%, 50%,
- 15 60%, 70%, 80%, 90% or even 100% of the Q groups are blocking groups.

Preferred blocking groups are electron-withdrawing groups. Without wishing to be bound by theory, it is believed that glycosidic bonds are unstable to hydrolysis due to assistance from an intramolecular nucleophilic attack of a saccharide hydroxyl group on the glycosidic linkage (*i.e.* by formation of a cyclic intermediate). The greater the nucleophilicity of the hydroxyl group, the greater

20 the tendency for intramolecular nucleophilic attack. An electron-withdrawing blocking group has the effect of delocalizing the oxygen lone pair, thereby decreasing the oxygen nucleophilicity and decreasing the tendency for intramolecular nucleophilic attack.

For protecting against serogroup A, therefore, the aqueous compositions can include a MenA modified saccharide as defined above.

- 25 Preferred compositions of the invention can be stored for 28 days at 37°C and, after that period, less than  $f\%$  of the initial total amount of conjugated MenA saccharide will be unconjugated, where  $f$  is 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 or lower.

### Covalent conjugation

Capsular saccharides in compositions of the invention will usually be conjugated to carrier protein(s).

- 30 In general, conjugation enhances the immunogenicity of saccharides as it converts them from T-independent antigens to T-dependent antigens, thus allowing priming for immunological memory.

Conjugation is particularly useful for paediatric vaccines and is a well known technique [e.g. reviewed in refs. 15 to 24].

Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria toxoid or tetanus toxoid. The CRM<sub>197</sub> diphtheria toxoid [25-27] is particularly preferred. Other suitable carrier proteins include the *N.meningitidis* outer membrane protein [28], synthetic peptides [29,30], heat shock proteins [31,32], pertussis proteins [33,34], cytokines [35], lymphokines [35], hormones [35], growth factors [35], artificial proteins comprising multiple human CD4<sup>+</sup> T cell epitopes from various pathogen-derived antigens [36], protein D from *H.influenzae* [37,38], pneumococcal surface protein PspA [39], iron-uptake proteins [40], toxin A or B from *C.difficile* [41], etc. Preferred carriers are diphtheria toxoid, tetanus toxoid, *H.influenzae* protein D, and CRM<sub>197</sub>.

Within a composition of the invention, it is possible to use more than one carrier protein e.g. to reduce the risk of carrier suppression. Thus different carrier proteins can be used for different serogroups e.g. serogroup A saccharides might be conjugated to CRM<sub>197</sub> while serogroup C saccharides might be conjugated to tetanus toxoid. It is also possible to use more than one carrier protein for a particular saccharide antigen e.g. serogroup A saccharides might be in two groups, with some conjugated to CRM<sub>197</sub> and others conjugated to tetanus toxoid. In general, however, it is preferred to use the same carrier protein for all serogroups, with CRM<sub>197</sub> being the preferred choice.

A single carrier protein might carry more than one saccharide antigen [42]. For example, a single carrier protein might have conjugated to it saccharides from serogroups A and C. To achieve this goal, saccharides can be mixed prior to the conjugation reaction. In general, however, it is preferred to have separate conjugates for each serogroup.

Conjugates with a saccharide:protein ratio (w/w) of between 1:5 (i.e. excess protein) and 5:1 (i.e. excess saccharide) are preferred. Ratios between 1:2 and 5:1 are preferred, as are ratios between 1:1.25 and 1:2.5 are more preferred. Excess carrier protein may be preferred for MenA and MenC.

Conjugates may be used in conjunction with free carrier protein [43]. When a given carrier protein is present in both free and conjugated form in a composition of the invention, the unconjugated form is preferably no more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight.

Any suitable conjugation reaction can be used, with any suitable linker where necessary.

The saccharide will typically be activated or functionalised prior to conjugation. Activation may involve, for example, cyanylating reagents such as CDAP (e.g. 1-cyano-4-dimethylamino pyridinium tetrafluoroborate [44,45,etc.]). Other suitable techniques use carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU; see also the introduction to reference 22).

Linkages via a linker group may be made using any known procedure, for example, the procedures described in references 46 and 47. One type of linkage involves reductive amination of the polysaccharide, coupling the resulting amino group with one end of an adipic acid linker group, and then coupling a protein to the other end of the adipic acid linker group [20,48,49]. Other linkers include B-propionamido [50], nitrophenyl-ethylamine [51], haloacyl halides [52], glycosidic linkages [53], 6-aminocaproic acid [54], ADH [55], C<sub>4</sub> to C<sub>12</sub> moieties [56] *etc.* As an alternative to using a linker, direct linkage can be used. Direct linkages to the protein may comprise oxidation of the polysaccharide followed by reductive amination with the protein, as described in, for example, references 57 and 58.

A process involving the introduction of amino groups into the saccharide (*e.g.* by replacing terminal =O groups with -NH<sub>2</sub>) followed by derivatisation with an adipic diester (*e.g.* adipic acid N-hydroxysuccinimido diester) and reaction with carrier protein is preferred. Another preferred reaction uses CDAP activation with a protein D carrier *e.g.* for MenA or MenC.

After conjugation, free and conjugated saccharides can be separated. There are many suitable methods, including hydrophobic chromatography, tangential ultrafiltration, diafiltration, *etc.* [see also refs. 59 & 60, *etc.*].

Where the composition of the invention includes a conjugated oligosaccharide, it is preferred that oligosaccharide preparation precedes conjugation.

### ***Oligosaccharides***

Capsular saccharides will generally be used in the form of oligosaccharides. These are conveniently formed by fragmentation of purified capsular polysaccharide (*e.g.* by hydrolysis), which will usually be followed by purification of the fragments of the desired size.

Fragmentation of polysaccharides is preferably performed to give a final average degree of polymerisation (DP) in the oligosaccharide of less than 30 (*e.g.* between 10 and 20, preferably around 10 for serogroup A; between 15 and 25 for serogroups W135 and Y, preferably around 15-20; between 12 and 22 for serogroup C; *etc.*). DP can conveniently be measured by ion exchange chromatography or by colorimetric assays [61].

If hydrolysis is performed, the hydrolysate will generally be sized in order to remove short-length oligosaccharides [62]. This can be achieved in various ways, such as ultrafiltration followed by ion-exchange chromatography. Oligosaccharides with a degree of polymerisation of less than or equal to about 6 are preferably removed for serogroup A, and those less than around 4 are preferably removed for serogroups W135 and Y.

### ***Serogroup B***

Vaccines against pathogens such as hepatitis B virus, diphtheria and tetanus typically contain a single protein antigen (*e.g.* the HBV surface antigen, or a tetanus toxoid). In contrast, acellular whooping

cough vaccines typically contain at least three *B.pertussis* proteins and the PrevNar™ pneumococcal vaccine contains seven separate conjugated saccharide antigens. Other vaccines such as cellular pertussis vaccines, the measles vaccine, the inactivated polio vaccine (IPV) and meningococcal OMV vaccines are by their very nature complex mixtures of a large number of antigens. Whether protection against can be elicited by a single antigen, a small number of defined antigens, or a complex mixture of undefined antigens, therefore depends on the pathogen in question.

As mentioned above, a vaccine against serogroup B meningococcus has proved elusive. OMV-based vaccines show narrow efficacy. Moreover, the large number of undefined antigens present in an OMV, combined with their variable nature, means that OMVs have various quality control problems.

The inventors have found that broad protection against serogroup B infection can be achieved, and that this can be achieved by using a small number of defined serogroup B polypeptide antigens, and so the compositions of the invention include one or more polypeptide antigens such that the composition can induce an immune response that is bactericidal against two or more (*i.e.* 2 or 3) of hypervirulent lineages A4, ET-5 and lineage 3 of *N.meningitidis* serogroup B.

Genome sequences for meningococcal serogroups A [63] and B [64,65] have been reported, and suitable antigens can be selected from the encoded polypeptides [*e.g.* refs. 66-71]. Candidate antigens have been manipulated to improve heterologous expression [refs. 72 to 74].

Preferred compositions include one or more of the following five antigens [75]: (1) a 'NadA' protein, preferably in oligomeric form (*e.g.* in trimeric form); (2) a '741' protein; (3) a '936' protein; (4) a '953' protein; and (5) a '287' protein.

'NadA' (Neisserial adhesin A) from MenB is disclosed as protein '961' in reference 69 (SEQ IDs 2943 & 2944) and as 'NMB1994' in reference 64 (see also GenBank accession numbers: 11352904 & 7227256). A detailed study of the protein can be found in reference 76. When used according to the present invention, NadA may take various forms. Preferred forms of NadA are truncation or deletion variants, such as those disclosed in references 72 to 74. In particular, NadA without its C-terminal membrane anchor is preferred (*e.g.* deletion of residues 351-405 for the 2996 strain, to give SEQ ID NO:1 herein), which is sometimes distinguished herein by the use of a 'C' superscript *e.g.* NadA<sup>(C)</sup>. Expression of NadA without its membrane anchor domain in *E.coli* results in secretion of the protein into the culture supernatant with concomitant removal of its 23mer leader peptide (*e.g.* to leave a 327mer for strain 2996 [SEQ ID NO:2 herein]). Polypeptides without their leader peptides are sometimes distinguished herein by the use of a 'NL' superscript *e.g.* NadA<sup>(NL)</sup> or NadA<sup>(C)(NL)</sup>. Preferred NadA polypeptides have an amino acid sequence which: (a) has 50% or more identity (*e.g.* 60%, 70%, 80%, 90%, 95%, 99% or more) to SEQ ID NO:2; and/or (b) comprises a fragment of at least *n* consecutive amino acids of SEQ ID NO:1, wherein *n* is 7 or more (*e.g.* 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments for (b) lack one or more amino acids (*e.g.* 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or the N-terminus of SEQ ID NO:1 (*e.g.* NadA<sup>(C)</sup>, NadA<sup>(NL)</sup>, NadA<sup>(C)(NL)</sup>). Other preferred fragments comprise an epitope from SEQ ID 1, and a particularly preferred fragment of SEQ ID 1 is

SEQ ID 2. These various sequences includes NadA variants (e.g. allelic variants, homologs, orthologs, paralogs, mutants, *etc.*). Various NadA sequences are shown in Figure 9 of reference 77.

‘741’ protein from MenB is disclosed in reference 69 (SEQ IDs 2535 & 2536) and as ‘NMB1870’ in reference 64 (see also GenBank accession number GI:7227128). The corresponding protein in serogroup A [63] has GenBank accession number 7379322. 741 is naturally a lipoprotein. When used according to the present invention, 741 protein may take various forms. Preferred forms of 741 are truncation or deletion variants, such as those disclosed in references 72 to 74. In particular, the N-terminus of 741 may be deleted up to and including its poly-glycine sequence (*i.e.* deletion of residues 1 to 72 for strain MC58 [SEQ ID NO:3 herein]), which is sometimes distinguished herein by the use of a ‘ΔG’ prefix. This deletion can enhance expression. The deletion also removes 741’s lipidation site. Preferred 741 sequences have an amino acid sequence which: (a) has 50% or more identity (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more) to SEQ ID NO:3; and/or (b) comprises a fragment of at least *n* consecutive amino acids from SEQ ID NO:3, wherein *n* is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments for (b) comprise an epitope from 741. Other preferred fragments lack one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or the N-terminus of SEQ ID NO:3. These sequences include 741 variants (e.g. allelic variants, homologs, orthologs, paralogs, mutants, *etc.*). Various 741 sequences can be found in SEQ IDs 1 to 22 of reference 74, in SEQ IDs 1 to 23 of reference 78, and in SEQ IDs 1-299 of reference 79.

‘936’ protein from serogroup B is disclosed in reference 69 (SEQ IDs 2883 & 2884) and as ‘NMB2091’ in reference 64 (see also GenBank accession number GI:7227353). The corresponding gene in serogroup A [63] has GenBank accession number 7379093. When used according to the present invention, 936 protein may take various forms. Preferred forms of 936 are truncation or deletion variants, such as those disclosed in references 72 to 74. In particular, the N-terminus leader peptide of 936 may be deleted (e.g. deletion of residues 1 to 23 for strain MC58, to give 936<sup>NL</sup> [SEQ ID NO:4 herein]). Preferred 936 sequences have an amino acid sequence which: (a) has 50% or more identity (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more) to SEQ ID NO:4; and/or (b) comprises a fragment of at least *n* consecutive amino acids from SEQ ID NO:4, wherein *n* is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments for (b) comprise an epitope from 936. Other preferred fragments lack one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or the N-terminus of SEQ ID NO:4. These sequences include 936 variants (e.g. allelic variants, homologs, orthologs, paralogs, mutants, *etc.*).

‘953’ protein from serogroup B is disclosed in reference 69 (SEQ IDs 2917 & 2918) and as ‘NMB1030’ in reference 64 (see also GenBank accession number GI:7226269). The corresponding protein in serogroup A [63] has GenBank accession number 7380108. When used according to the present invention, 953 protein may take various forms. Preferred forms of 953 are truncation or deletion variants, such as those disclosed in references 72 to 74. In particular, the N-terminus leader

peptide of 953 may be deleted (e.g. deletion of residues 1 to 19 for strain MC58, to give 953<sup>NL</sup> [SEQ ID NO:5 herein]. Preferred 953 sequences have an amino acid sequence which: (a) has 50% or more identity (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more) to SEQ ID NO:5; and/or (b) comprises a fragment of at least *n* consecutive amino acids from SEQ ID NO:5, wherein *n* is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments for (b) comprise an epitope from 953. Other preferred fragments lack one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or the N-terminus of SEQ ID NO:5. These sequences include 936 variants (e.g. allelic variants, homologs, orthologs, paralogs, mutants, *etc.*). Allelic forms of 953 can be seen in Figure 19 of reference 71.

‘287’ protein from serogroup B is disclosed in reference 69 (SEQ IDs 3103 & 3104), as ‘NMB2132’ in reference 64, and as ‘GNA2132’ in reference 66 (see also GenBank accession number GI:7227388). The corresponding protein in serogroup A [63] has GenBank accession number 7379057. When used according to the present invention, 287 protein may take various forms. Preferred forms of 287 are truncation or deletion variants, such as those disclosed in references 72 to 74. In particular, the N-terminus of 287 may be deleted up to and including its poly-glycine sequence (e.g. deletion of residues 1 to 24 for strain MC58, to give ΔG287 [SEQ ID NO:6 herein]. This deletion can enhance expression. Preferred 287 sequences have an amino acid sequence which: (a) has 50% or more identity (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more) to SEQ ID NO:6; and/or (b) comprises a fragment of at least *n* consecutive amino acids from SEQ ID NO:6, wherein *n* is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments for (b) comprise an epitope from 287. Other preferred fragments lack one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or the N-terminus of SEQ ID NO:6. These sequences include 287 variants (e.g. allelic variants, homologs, orthologs, paralogs, mutants, *etc.*). Allelic forms of 287 can be seen in Figures 5 and 15 of reference 71, and in example 13 and figure 21 of reference 69 (SEQ IDs 3179 to 3184).

Preferred MenB antigens comprise an amino acid sequence found in one of strains are 2996, MC58, 95N477, and 394/98. Protein 287 is preferably from strain 2996 or, more preferably, from strain 394/98. Protein 741 is preferably from serogroup B strains MC58, 2996, 394/98, or 95N477, or from serogroup C strain 90/18311. Strain MC58 is more preferred. Proteins 936, 953 and NadA are preferably from strain 2996. Where a composition includes a particular protein antigen (e.g. 741 or 287), the composition can include that antigen in more than one variant form e.g. the same protein, but from more than one strain. These proteins may be included as tandem or separate proteins.

In some embodiments, however, the composition of the invention includes the same protein but from more than one strain. This approach has been found to be effective with the 741 protein. This protein is an extremely effective antigen for eliciting anti-meningococcal antibody responses, and it is expressed across all meningococcal serogroups. Phylogenetic analysis shows that the protein splits into two groups, and that one of these splits again to give three variants in total [80], and while serum raised against a given variant is bactericidal within the same variant group, it is not active against

strains which express one of the other two variants *i.e.* there is intra-variant cross-protection, but not inter-variant cross-protection [78,80]. For maximum cross-strain efficacy, therefore, it is preferred that a composition should include more than one variant of protein 741. An exemplary sequence from each variant is given in SEQ ID NO<sup>s</sup>: 10, 11 and 12 herein, starting with a N-terminal cysteine residue to which lipid will be covalently attached in the native lipoprotein form. It is therefore preferred that the composition should include at least two of: (1) a first protein, comprising an amino acid sequence having at least *a*% sequence identity to SEQ ID NO:10 and/or comprising an amino acid sequence consisting of a fragment of at least *x* contiguous amino acids from SEQ ID NO:10; (2) a second protein, comprising an amino acid sequence having at least *b*% sequence identity to SEQ ID NO:11 and/or comprising an amino acid sequence consisting of a fragment of at least *y* contiguous amino acids from SEQ ID NO:11; and (3) a third protein, comprising an amino acid sequence having at least *c*% sequence identity to SEQ ID NO:12 and/or comprising an amino acid sequence consisting of a fragment of at least *z* contiguous amino acids from SEQ ID NO:12. The value of *a* is at least 85 *e.g.* 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or more. The value of *b* is at least 85 *e.g.* 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or more. The value of *c* is at least 85 *e.g.* 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or more. The values of *a*, *b* and *c* are not intrinsically related to each other. The value of *x* is at least 7 *e.g.* 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250). The value of *y* is at least 7 *e.g.* 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250). The value of *z* is at least 7 *e.g.* 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250). The values of *x*, *y* and *z* are not intrinsically related to each other. It is preferred that any given 741 amino acid sequence will not fall into more than one of categories (1), (2) and (3). Any given 741 sequence will thus fall into only one of categories (1), (2) and (3). It is thus preferred that: protein (1) has less than *i*% sequence identity to protein (2); protein (1) has less than *j*% sequence identity to protein (3); and protein (2) has less than *k*% sequence identity to protein (3). The value of *i* is 60 or more (*e.g.* 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, *etc.*) and is at most *a*. The value of *j* is 60 or more (*e.g.* 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, *etc.*) and is at most *b*. The value of *k* is 60 or more (*e.g.* 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, *etc.*) and is at most *c*. The values of *i*, *j* and *k* are not intrinsically related to each other.

Compositions of the invention include a small number (*e.g.* fewer than *t* antigens, where *t* is 10, 9, 8, 7, 6, 5, 4 or 3) of purified serogroup B antigens. It is particularly preferred that the composition should not include complex or undefined mixtures of antigens *e.g.* it is preferred not to include outer membrane vesicles in the composition. The antigens are preferably expressed recombinantly in a heterologous host and then purified. For a composition including *t* MenB antigens, there may be *t* separate polypeptides but, to reduce complexity even further, it is preferred that at least two of the



antigens are expressed as a single polypeptide chain (a 'hybrid' protein [refs. 72 to 74]) *i.e.* such that the  $t$  antigens form fewer than  $t$  polypeptides. Hybrid proteins offer two principal advantages: first, a protein that may be unstable or poorly expressed on its own can be assisted by adding a suitable hybrid partner that overcomes the problem; second, commercial manufacture is simplified as only one expression and purification need be employed in order to produce two separately-useful proteins. A hybrid protein included in a composition of the invention may comprise two or more (*i.e.* 2, 3, 4 or 5) of the five antigens listed above. Hybrids consisting of two of the five antigens are preferred.

Within the combination of five basic antigens (NadA, 741, 953, 936 & 287), an antigen may be present in more than one hybrid protein and/or as a non-hybrid protein. It is preferred, however, that an antigen is present either as a hybrid or as a non-hybrid, but not as both, although it may be useful to include protein 741 both as a hybrid and a non-hybrid (preferably lipoprotein) antigen, particularly where more than one variant of 741 is used.

Hybrid proteins can be represented by the formula  $\text{NH}_2\text{-A-}[\text{-X-L-}]_n\text{-B-COOH}$ , wherein: X is an amino acid sequence of one of the five basic antigens; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; and  $n$  is 2, 3, 4 or 5.

Most preferably,  $n$  is 2. Two-antigen hybrids for use in the invention comprise: NadA & 741; NadA & 936; NadA & 953; NadA & 287; 741 & 936; 741 & 953; 741 & 287; 936 & 953; 936 & 287; 953 & 287. Two preferred proteins are:  $X_1$  is a 936 and  $X_2$  is a 741;  $X_1$  is a 287 and  $X_2$  is a 953.

If a -X- moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in the hybrid protein. In some embodiments, the leader peptides will be deleted except for that of the -X- moiety located at the N-terminus of the hybrid protein *i.e.* the leader peptide of  $X_1$  will be retained, but the leader peptides of  $X_2 \dots X_n$  will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of  $X_1$  as moiety -A-.

For each  $n$  instances of [-X-L-], linker amino acid sequence -L- may be present or absent. For instance, when  $n=2$  the hybrid may be  $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-L}_2\text{-COOH}$ ,  $\text{NH}_2\text{-X}_1\text{-X}_2\text{-COOH}$ ,  $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-COOH}$ ,  $\text{NH}_2\text{-X}_1\text{-X}_2\text{-L}_2\text{-COOH}$ , *etc.* Linker amino acid sequence(s) -L- will typically be short (*e.g.* 20 or fewer amino acids *i.e.* 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples comprise short peptide sequences which facilitate cloning, poly-glycine linkers (*i.e.* comprising  $\text{Gly}_n$  where  $n = 2, 3, 4, 5, 6, 7, 8, 9, 10$  or more), and histidine tags (*i.e.*  $\text{His}_n$  where  $n = 3, 4, 5, 6, 7, 8, 9, 10$  or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG (SEQ ID 9), with the Gly-Ser dipeptide being formed from a *Bam*HI restriction site, thus aiding cloning and manipulation, and the  $(\text{Gly})_4$  tetrapeptide being a typical poly-glycine linker. If  $X_{n+1}$  is a  $\Delta\text{G}$  protein and  $L_n$  is a glycine linker, this may be equivalent to  $X_{n+1}$  not being a  $\Delta\text{G}$  protein and  $L_n$  being absent.

-A- is an optional N-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18,



17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include leader sequences to direct protein trafficking, or short peptide sequences which facilitate cloning or purification (e.g. histidine tags *i.e.* His<sub>n</sub> where *n* = 3, 4, 5, 6, 7, 8, 9, 10 or more). Other suitable N-terminal amino acid sequences will be apparent to those skilled in the art. If X<sub>1</sub> lacks its own N-terminus methionine, -A- is preferably an oligopeptide (e.g. with 1, 2, 3, 4, 5, 6, 7 or 8 amino acids) which provides a N-terminus methionine.

-B- is an optional C-terminal amino acid sequence. This will typically be short (e.g. 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include sequences to direct protein trafficking, short peptide sequences which facilitate cloning or purification (e.g. comprising histidine tags *i.e.* His<sub>n</sub> where *n* = 3, 4, 5, 6, 7, 8, 9, 10 or more), or sequences which enhance protein stability. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.

Two particularly preferred hybrid proteins of the invention are as follows:

<i>n</i>	A	X <sub>1</sub>	L <sub>1</sub>	X <sub>2</sub>	L <sub>2</sub>	B	SEQ ID NO:
2	MA	ΔG287	GSGGGG	953 <sup>(NL)</sup>	—	—	7
2	M	936 <sup>(NL)</sup>	GSGGGG	ΔG741	—	—	8

These two proteins may be used in combination with NadA (particularly with SEQ ID NO:2). Thus a preferred composition of MenB antigens for use with the invention thus includes a first polypeptide comprising amino acid sequence SEQ ID NO:2, a second polypeptide comprising amino acid sequence SEQ ID NO:7 and a third polypeptide comprising amino acid sequence SEQ ID NO:8. This is a preferred group of MenB antigens for use with the invention.

As mentioned above, compositions of the invention can induce a serum bactericidal antibody response that is effective against two or three of MenB hypervirulent lineages A4, ET-5 and lineage 3. They may additionally induce bactericidal antibody responses against one or more of hypervirulent lineages subgroup I, subgroup III, subgroup IV-1 or ET-37 complex, and against other lineages *e.g.* hyperinvasive lineages. These antibody responses are conveniently measured in mice and are a standard indicator of vaccine efficacy [*e.g.* see end-note 14 of reference 66]. Serum bactericidal activity (SBA) measures bacterial killing mediated by complement, and can be assayed using human or baby rabbit complement. WHO standards require a vaccine to induce at least a 4-fold rise in SBA in more than 90% of recipients.

The composition need not induce bactericidal antibodies against each and every MenB strain within these hypervirulent lineages; rather, for any given group of four or more strains of serogroup B meningococcus within a particular hypervirulent lineage, the antibodies induced by the composition are bactericidal against at least 50% (*e.g.* 60%, 70%, 80%, 90% or more) of the group. Preferred groups of strains will include strains isolated in at least four of the following countries: GB, AU, CA, NO, IT, US, NZ, NL, BR, and CU. The serum preferably has a bactericidal titre of at least 1024 (*e.g.*

2<sup>10</sup>, 2<sup>11</sup>, 2<sup>12</sup>, 2<sup>13</sup>, 2<sup>14</sup>, 2<sup>15</sup>, 2<sup>16</sup>, 2<sup>17</sup>, 2<sup>18</sup> or higher, preferably at least 2<sup>14</sup>) i.e. the serum is able to kill at least 50% of test bacteria of a particular strain when diluted 1/1024, as described in reference 66.

Preferred compositions can induce bactericidal responses against the following strains of serogroup B meningococcus: (i) from cluster A4, strain 961-5945 (B:2b:P1.21,16) and/or strain G2136 (B:-);  
5 (ii) from ET-5 complex, strain MC58 (B:15:P1.7,16b) and/or strain 44/76 (B:15:P1.7,16); (iii) from lineage 3, strain 394/98 (B:4:P1.4) and/or strain BZ198 (B:NT:-). More preferred compositions can induce bactericidal responses against strains 961-5945, 44/76 and 394/98. Strains 961-5945 and G2136 are both *Neisseria* MLST reference strains [ids 638 & 1002 in ref. 81]. Strain MC58 is widely available (e.g. ATCC BAA-335) and was the strain sequenced in reference 64. Strain 44/76 has been  
10 widely used and characterised (e.g. ref. 82) and is one of the *Neisseria* MLST reference strains [id 237 in ref. 81; row 32 of Table 2 in ref. 83]. Strain 394/98 was originally isolated in New Zealand in 1998, and there have been several published studies using this strain (e.g. refs. 84 & 85). Strain BZ198 is another MLST reference strain [id 409 in ref. 81; row 41 of Table 2 in ref. 83]. The composition may additionally induce a bactericidal response against serogroup W135 strain  
15 LNP17592 (W135:2a:P1.5,2), from ET-37 complex. This is a Haji strain isolated in France in 2000.

Other MenB polypeptide antigens which may be included in compositions of the invention include those comprising one of the following amino acid sequences: SEQ ID NO:650 from ref. 67; SEQ ID NO:878 from ref. 67; SEQ ID NO:884 from ref. 67; SEQ ID NO:4 from ref. 68; SEQ ID NO:598 from ref. 69; SEQ ID NO:818 from ref. 69; SEQ ID NO:864 from ref. 69; SEQ ID NO:866 from ref.  
20 69; SEQ ID NO:1196 from ref. 69; SEQ ID NO:1272 from ref. 69; SEQ ID NO:1274 from ref. 69; SEQ ID NO:1640 from ref. 69; SEQ ID NO:1788 from ref. 69; SEQ ID NO:2288 from ref. 69; SEQ ID NO:2466 from ref. 69; SEQ ID NO:2554 from ref. 69; SEQ ID NO:2576 from ref. 69; SEQ ID NO:2606 from ref. 69; SEQ ID NO:2608 from ref. 69; SEQ ID NO:2616 from ref. 69; SEQ ID NO:2668 from ref. 69; SEQ ID NO:2780 from ref. 69; SEQ ID NO:2932 from ref. 69; SEQ ID  
25 NO:2958 from ref. 69; SEQ ID NO:2970 from ref. 69; SEQ ID NO:2988 from ref. 69, or a polypeptide comprising an amino acid sequence which: (a) has 50% or more identity (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more) to said sequences; and/or (b) comprises a fragment of at least *n* consecutive amino acids from said sequences, wherein *n* is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments for (b) comprise  
30 an epitope from the relevant sequence. More than one (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more) of these polypeptides may be included.

#### ***Further antigenic components***

Non-meningococcal and non-neisserial antigens, preferably ones that do not diminish the immune response against the meningococcal components, may also be included in compositions of the  
35 invention. Ref. 86, for instance, discloses combinations of oligosaccharides from *N.meningitidis* serogroups B and C together with the Hib saccharide. Particularly preferred non-meningococcal antigens include:

- a diphtheria antigen, such as a diphtheria toxoid [e.g. chapter 3 of ref.87].

- a tetanus antigen, such as a tetanus toxoid [e.g. chapter 4 of ref. 87].
  - pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B.pertussis*, optionally also in combination with pertactin and/or agglutinogens 2 and 3 [e.g. refs. 88 & 89].
  - cellular pertussis antigen.
- 5    — an antigen from hepatitis A virus, such as inactivated virus [e.g. 90, 91].
- an antigen from hepatitis B virus, such as the surface and/or core antigens [e.g. 91,92], with surface antigen preferably being adsorbed onto an aluminium phosphate [93].
  - polio antigen(s) [e.g. 94, 95] such as IPV.

The mixture may comprise one or more of these further antigens, which may be detoxified where necessary (e.g. detoxification of pertussis toxin by chemical and/or genetic means).

Where a diphtheria antigen is included in the mixture it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.

15    Antigens in the mixture will typically be present at a concentration of at least 1µg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen. It is preferred that the protective efficacy of individual saccharide antigens is not removed by combining them, although actual immunogenicity (e.g. ELISA titres) may be reduced.

20    As an alternative to using proteins antigens in the mixture, nucleic acid encoding the antigen may be used. Protein components of the mixture may thus be replaced by nucleic acid (preferably DNA e.g. in the form of a plasmid) that encodes the protein. Similarly, compositions of the invention may comprise proteins which mimic saccharide antigens e.g. mimotopes [96] or anti-idiotypic antibodies. These may replace individual saccharide components, or may supplement them. As an example, the vaccine may comprise a peptide mimic of the MenC [97] or the MenA [98] capsular polysaccharide

25    in place of the saccharide itself.

Two preferred non-meningococcal antigens for inclusion in compositions of the invention are those which protect against *H.influenzae* type B (Hib) and against *Streptococcus pneumoniae*.

#### *Haemophilus influenzae* type B (Hib)

30    Where the composition includes a *H.influenzae* type B antigen, it will typically be a Hib capsular saccharide antigen. Saccharide antigens from *H.influenzae* b are well known.

Advantageously, the Hib saccharide is covalently conjugated to a carrier protein, in order to enhance its immunogenicity, especially in children. The preparation of polysaccharide conjugates in general, and of the Hib capsular polysaccharide in particular, is well documented [e.g. references 16-24, etc.]. The invention may use any suitable Hib conjugate. Suitable carrier proteins are described above, and

35    preferred carriers for Hib saccharides are CRM<sub>197</sub> ('HbOC'), tetanus toxoid ('PRP-T') and the outer membrane complex of *N.meningitidis* ('PRP-OMP').

The saccharide moiety of the conjugate may be a polysaccharide (e.g. full-length polyribosylribitol phosphate (PRP)), but it is preferred to hydrolyse polysaccharides to form oligosaccharides (e.g. MW from ~1 to ~5 kDa).

A preferred conjugate comprises a Hib oligosaccharide covalently linked to CRM<sub>197</sub> via an adipic acid linker [99, 100]. Tetanus toxoid is also a preferred carrier.

Administration of the Hib antigen preferably results in an anti-PRP antibody concentration of  $\geq 0.15 \mu\text{g/ml}$ , and more preferably  $\geq 1 \mu\text{g/ml}$ .

Where a composition includes a Hib saccharide antigen, it is preferred that it does not also include an aluminium hydroxide adjuvant. If the composition includes an aluminium phosphate adjuvant then the Hib antigen may be adsorbed to the adjuvant [101] or it may be non-adsorbed [102]. Prevention of adsorption can be achieved by selecting the correct pH during antigen/adjuvant mixing, an adjuvant with an appropriate point of zero charge, and an appropriate order of mixing for the various different antigens in a composition [103].

Compositions of the invention may comprise more than one Hib antigen. Hib antigens may be lyophilised e.g. for reconstitution by meningococcal compositions of the invention.

#### *Streptococcus pneumoniae*

Where the composition includes a *S.pneumoniae* antigen, it will typically be a capsular saccharide antigen which is preferably conjugated to a carrier protein [e.g. refs. 104 to 106]. It is preferred to include saccharides from more than one serotype of *S.pneumoniae*. For example, mixtures of polysaccharides from 23 different serotype are widely used, as are conjugate vaccines with polysaccharides from between 5 and 11 different serotypes [107]. For example, PreVNar™ [1] contains antigens from seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) with each saccharide individually conjugated to CRM<sub>197</sub> by reductive amination, with 2  $\mu\text{g}$  of each saccharide per 0.5ml dose (4  $\mu\text{g}$  of serotype 6B), and with conjugates adsorbed on an aluminium phosphate adjuvant. Compositions of the invention preferably include at least serotypes 6B, 14, 19F and 23F. Conjugates may be adsorbed onto an aluminium phosphate.

As an alternative to using saccharide antigens from pneumococcus, the composition may include one or more polypeptide antigens. Genome sequences for several strains of pneumococcus are available [108,109] and can be subjected to reverse vaccinology [110-113] to identify suitable polypeptide antigens [114,115]. For example, the composition may include one or more of the following antigens: PhtA, PhtD, PhtB, PhtE, SpsA, LytB, LytC, LytA, Sp125, Sp101, Sp128, Sp130 and Sp130, as defined in reference 116. The composition may include more than one (e.g. 2, 3, 4, 5, 6, 7, 8, 9 10, 11, 12, 13 or 14) of these antigens.

In some embodiments, the composition may include both saccharide and polypeptide antigens from pneumococcus. These may be used in simple admixture, or the pneumococcal saccharide antigen

may be conjugated to a pneumococcal protein. Suitable carrier proteins for such embodiments include the antigens listed in the previous paragraph [116].

Pneumococcal antigens may be lyophilised *e.g.* together with Hib antigen.

### ***Pharmaceutical compositions***

- 5 The composition of the invention will typically, in addition to the components mentioned above, comprise one or more 'pharmaceutically acceptable carriers', which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose [117], trehalose [118], lactose, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The vaccines may also contain diluents, such as water, saline, glycerol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile pyrogen-free, phosphate-buffered physiologic saline is a typical carrier. A thorough discussion of pharmaceutically acceptable excipients is available in reference 119.

Compositions of the invention are in aqueous form *i.e.* solutions or suspensions. Liquid formulation of this type allows the compositions to be administered direct from their packaged form, without the need for reconstitution in an aqueous medium, and are thus ideal for injection. Compositions may be presented in vials, or they may be presented in ready-filled syringes. The syringes may be supplied with or without needles. A syringe will include a single dose of the composition, whereas a vial may include a single dose or multiple doses.

Liquid compositions of the invention are also suitable for reconstituting other vaccines from a lyophilised form *e.g.* to reconstitute lyophilised Hib or DTP antigens. Where a composition of the invention is to be used for such extemporaneous reconstitution, the invention provides a kit, which may comprise two vials, or may comprise one ready-filled syringe and one vial, with the contents of the syringe being used to reactivate the contents of the vial prior to injection.

Compositions of the invention may be packaged in unit dose form or in multiple dose form. For multiple dose forms, vials are preferred to pre-filled syringes. Effective dosage volumes can be routinely established, but a typical human dose of the composition for injection has a volume of 0.5ml.

The pH of the composition is preferably between 6 and 8, preferably about 7. Stable pH may be maintained by the use of a buffer. If a composition comprises an aluminium hydroxide salt, it is preferred to use a histidine buffer [120]. The composition may be sterile and/or pyrogen-free. Compositions of the invention may be isotonic with respect to humans.

- 35 Compositions of the invention are immunogenic, and are more preferably vaccine compositions. Vaccines according to the invention may either be prophylactic (*i.e.* to prevent infection) or

therapeutic (*i.e.* to treat infection), but will typically be prophylactic. Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (*e.g.* non-human primate, primate, *etc.*), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

Within each dose, the quantity of an individual saccharide antigen will generally be between 1-50  $\mu\text{g}$  (measured as mass of saccharide) *e.g.* about 1 $\mu\text{g}$ , about 2.5 $\mu\text{g}$ , about 4 $\mu\text{g}$ , about 5 $\mu\text{g}$ , or about 10 $\mu\text{g}$ .

Each saccharide may be present at substantially the same quantity per dose. However, the ratio (w/w) of MenY saccharide:MenW135 saccharide may be greater than 1 (*e.g.* 2:1, 3:1, 4:1, 5:1, 10:1 or higher) and/or the ratio (w/w) of MenY saccharide:MenC saccharide may be less than 1 (*e.g.* 1:2, 1:3, 1:4, 1:5, or lower).

Preferred ratios (w/w) for saccharides from serogroups A:C:W135:Y are: 1:1:1:1; 1:1:1:2; 2:1:1:1; 4:2:1:1; 8:4:2:1; 4:2:1:2; 8:4:1:2; 4:2:2:1; 2:2:1:1; 4:4:2:1; 2:2:1:2; 4:4:1:2; and 2:2:2:1. Preferred ratios (w/w) for saccharides from serogroups C:W135:Y are: 1:1:1; 1:1:2; 1:1:1; 2:1:1; 4:2:1; 2:1:2; 4:1:2; 2:2:1; and 2:1:1. Using a substantially equal mass of each saccharide is preferred.

Preferred compositions of the invention comprise less than 50  $\mu\text{g}$  meningococcal saccharide per dose. Other preferred compositions comprise  $\leq 40$   $\mu\text{g}$  meningococcal saccharide per dose. Other preferred compositions comprise  $\leq 30$   $\mu\text{g}$  meningococcal saccharide per dose. Other preferred compositions comprise  $\leq 25$   $\mu\text{g}$  meningococcal saccharide per dose. Other preferred compositions comprise  $\leq 20$   $\mu\text{g}$  meningococcal saccharide per dose. Other preferred compositions comprise  $\leq 10$   $\mu\text{g}$  meningococcal saccharide per dose but, ideally, compositions of the invention comprise at least 10  $\mu\text{g}$  total meningococcal saccharide per dose.

Compositions of the invention may include an antimicrobial, particularly when packaged in multiple dose format.

Compositions of the invention may comprise detergent *e.g.* a Tween (polysorbate), such as Tween 80. Detergents are generally present at low levels *e.g.*  $<0.01\%$ .

Compositions of the invention may include sodium salts (*e.g.* sodium chloride) to give tonicity. A concentration of  $10 \pm 2 \text{ mg/ml}$  NaCl is typical.

Compositions of the invention will generally include a buffer. A phosphate buffer is typical.

Compositions of the invention will generally be administered in conjunction with other immunoregulatory agents. In particular, compositions will usually include one or more adjuvants. Such adjuvants include, but are not limited to:

A. Mineral-containing compositions

- 5 Mineral containing compositions suitable for use as adjuvants in the invention include mineral salts, such as aluminium salts and calcium salts. The invention includes mineral salts such as hydroxides (e.g. oxyhydroxides), phosphates (e.g. hydroxyphosphates, orthophosphates), sulphates, *etc.* [e.g. see chapters 8 & 9 of ref. 121], or mixtures of different mineral compounds, with the compounds taking any suitable form (e.g. gel, crystalline, amorphous, *etc.*), and with adsorption being preferred. The  
10 mineral containing compositions may also be formulated as a particle of metal salt [122].

B. Oil Emulsions

- Oil emulsion compositions suitable for use as adjuvants in the invention include squalene-water emulsions, such as MF59 [Chapter 10 of ref. 121; see also ref. 123] (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer). Complete Freund's  
15 adjuvant (CFA) and incomplete Freund's adjuvant (IFA) may also be used.

C. Saponin formulations [chapter 22 of ref. 121]

- Saponin formulations may also be used as adjuvants in the invention. Saponins are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the *Quillaia saponaria*  
20 Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from *Smilax ornata* (sarsapilla), *Gypsophilla paniculata* (brides veil), and *Saponaria officianalis* (soap root). Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs. QS21 is marketed as Stimulon™.

- Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. Preferably, the saponin is QS21. A method of production of QS21 is disclosed in ref. 124. Saponin formulations may also comprise a sterol, such as cholesterol [125].  
25

- Combinations of saponins and cholesterol can be used to form unique particles called immunostimulating complexes (ISCOMs) [chapter 23 of ref. 121]. ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of Quila, QHA and QHC. ISCOMs are further described in refs. 125-127. Optionally, the ISCOMS may be devoid of additional detergent [128].  
30

A review of the development of saponin based adjuvants can be found in refs. 129 & 130.

- 35 D. Virosomes and virus-like particles

Virosomes and virus-like particles (VLPs) can also be used as adjuvants in the invention. These structures generally contain one or more proteins from a virus optionally combined or formulated

with a phospholipid. They are generally non-pathogenic, non-replicating and generally do not contain any of the native viral genome. The viral proteins may be recombinantly produced or isolated from whole viruses. These viral proteins suitable for use in virosomes or VLPs include proteins derived from influenza virus (such as HA or NA), Hepatitis B virus (such as core or capsid proteins), Hepatitis E virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk virus, human Papilloma virus, HIV, RNA-phages, Q $\beta$ -phage (such as coat proteins), GA-phage, fr-phage, AP205 phage, and Ty (such as retrotransposon Ty protein p1). VLPs are discussed further in refs. 131-136. Virosomes are discussed further in, for example, ref. 137

#### E. Bacterial or microbial derivatives

Adjuvants suitable for use in the invention include bacterial or microbial derivatives such as non-toxic derivatives of enterobacterial lipopolysaccharide (LPS), Lipid A derivatives, immunostimulatory oligonucleotides and ADP-ribosylating toxins and detoxified derivatives thereof.

Non-toxic derivatives of LPS include monophosphoryl lipid A (MPL) and 3-O-deacylated MPL (3dMPL). 3dMPL is a mixture of 3 de-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains. A preferred "small particle" form of 3 De-O-acylated monophosphoryl lipid A is disclosed in ref. 138. Such "small particles" of 3dMPL are small enough to be sterile filtered through a 0.22 $\mu$ m membrane [138]. Other non-toxic LPS derivatives include monophosphoryl lipid A mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g. RC-529 [139,140].

Lipid A derivatives include derivatives of lipid A from *Escherichia coli* such as OM-174. OM-174 is described for example in refs. 141 & 142.

Immunostimulatory oligonucleotides suitable for use as adjuvants in the invention include nucleotide sequences containing a CpG motif (a dinucleotide sequence containing an unmethylated cytosine linked by a phosphate bond to a guanosine). Double-stranded RNAs and oligonucleotides containing palindromic or poly(dG) sequences have also been shown to be immunostimulatory.

The CpG's can include nucleotide modifications/analogues such as phosphorothioate modifications and can be double-stranded or single-stranded. References 143, 144 and 145 disclose possible analog substitutions e.g. replacement of guanosine with 2'-deoxy-7-deazaguanosine. The adjuvant effect of CpG oligonucleotides is further discussed in refs. 146-151.

The CpG sequence may be directed to TLR9, such as the motif GTCGTT or TTCGTT [152]. The CpG sequence may be specific for inducing a Th1 immune response, such as a CpG-A ODN, or it may be more specific for inducing a B cell response, such as a CpG-B ODN. CpG-A and CpG-B ODNs are discussed in refs. 153-155. Preferably, the CpG is a CpG-A ODN.

Preferably, the CpG oligonucleotide is constructed so that the 5' end is accessible for receptor recognition. Optionally, two CpG oligonucleotide sequences may be attached at their 3' ends to form "immunomers". See, for example, refs. 152 & 156-158.

Bacterial ADP-ribosylating toxins and detoxified derivatives thereof may be used as adjuvants in the invention. Preferably, the protein is derived from *E.coli* (*E.coli* heat labile enterotoxin "LT"), cholera



(“CT”), or pertussis (“PT”). The use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in ref. 159 and as parenteral adjuvants in ref. 160. The toxin or toxoid is preferably in the form of a holotoxin, comprising both A and B subunits. Preferably, the A subunit contains a detoxifying mutation; preferably the B subunit is not mutated. Preferably, the adjuvant is a detoxified LT mutant such as LT-K63, LT-R72, and LT-G192. The use of ADP-ribosylating toxins and detoxified derivatives thereof, particularly LT-K63 and LT-R72, as adjuvants can be found in refs. 161-168. Numerical reference for amino acid substitutions is preferably based on the alignments of the A and B subunits of ADP-ribosylating toxins set forth in ref. 169, specifically incorporated herein by reference in its entirety.

10 F. Human immunomodulators

Human immunomodulators suitable for use as adjuvants in the invention include cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 [170], *etc.*) [171], interferons (*e.g.* interferon- $\gamma$ ), macrophage colony stimulating factor, and tumor necrosis factor.

G. Bioadhesives and Mucoadhesives

15 Bioadhesives and mucoadhesives may also be used as adjuvants in the invention. Suitable bioadhesives include esterified hyaluronic acid microspheres [172] or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrrolidone, polysaccharides and carboxymethylcellulose. Chitosan and derivatives thereof may also be used as adjuvants in the invention [173].

20 H. Microparticles

Microparticles may also be used as adjuvants in the invention. Microparticles (*i.e.* a particle of ~100nm to ~150 $\mu$ m in diameter, more preferably ~200nm to ~30 $\mu$ m in diameter, and most preferably ~500nm to ~10 $\mu$ m in diameter) formed from materials that are biodegradable and non-toxic (*e.g.* a poly( $\alpha$ -hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, *etc.*), with poly(lactide-co-glycolide) are preferred, optionally treated to have a negatively-charged surface (*e.g.* with SDS) or a positively-charged surface (*e.g.* with a cationic detergent, such as CTAB).

I. Liposomes (Chapters 13 & 14 of ref. 121)

Examples of liposome formulations suitable for use as adjuvants are described in refs. 174-176.

30 J. Polyoxyethylene ether and polyoxyethylene ester formulations

Adjuvants suitable for use in the invention include polyoxyethylene ethers and polyoxyethylene esters [177]. Such formulations further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol [178] as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol [179]. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.

### K. Polyphosphazene (PCPP)

PCPP formulations are described, for example, in refs. 180 and 181.

### L. Muramyl peptides

Examples of muramyl peptides suitable for use as adjuvants in the invention include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE).

### M. Imidazoquinolone Compounds.

Examples of imidazoquinolone compounds suitable for use adjuvants in the invention include Imiquamod and its homologues (e.g. "Resiquimod 3M"), described further in refs. 182 and 183.

The invention may also comprise combinations of aspects of one or more of the adjuvants identified above. For example, the following adjuvant compositions may be used in the invention: (1) a saponin and an oil-in-water emulsion [184]; (2) a saponin (e.g. QS21) + a non-toxic LPS derivative (e.g. 3dMPL) [185]; (3) a saponin (e.g. QS21) + a non-toxic LPS derivative (e.g. 3dMPL) + a cholesterol; (4) a saponin (e.g. QS21) + 3dMPL + IL-12 (optionally + a sterol) [186]; (5) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions [187]; (6) SAF, containing 10% squalane, 0.4% Tween 80™, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion. (7) Ribi™ adjuvant system (RAS), (Ribi Immunochem) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); and (8) one or more mineral salts (such as an aluminum salt) + a non-toxic derivative of LPS (such as 3dMPL).

Other substances that act as immunostimulating agents are disclosed in chapter 7 of ref. 121.

The use of aluminium salt adjuvants is particularly preferred, and antigens are generally adsorbed to such salts. The Menjugate™ and NeisVac™ MenC conjugates use a hydroxide adjuvant, whereas Meningitec™ uses a phosphate. It is possible in compositions of the invention to adsorb some antigens to an aluminium hydroxide but to have other antigens in association with an aluminium phosphate. In general, however, it is preferred to use only a single salt e.g. a hydroxide or a phosphate, but not both. Aluminium hydroxide is preferably avoided as an adjuvant, particularly if the composition includes a Hib antigen. Compositions that do not contain aluminium hydroxide are thus preferred. Rather, aluminium phosphates may be used, and a typical adjuvant is amorphous aluminium hydroxyphosphate with PO<sub>4</sub>/Al molar ratio between 0.84 and 0.92, included at 0.6mg Al<sup>3+</sup>/ml. Adsorption with a low dose of aluminium phosphate may be used e.g. between 50 and 100µg Al<sup>3+</sup> per conjugate per dose. Where an aluminium phosphate is used and it is desired not to adsorb an antigen to the adjuvant, this is favoured by including free phosphate ions in solution (e.g. by the use of a phosphate buffer).

Not all conjugates need to be adsorbed *i.e.* some or all can be free in solution.

Calcium phosphate is another preferred adjuvant.

## Methods of treatment

The invention also provides a method for raising an antibody response in a mammal, comprising administering a pharmaceutical composition of the invention to the mammal.

The invention provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention. The immune response is preferably protective and preferably involves antibodies. The method may raise a booster response.

The mammal is preferably a human. Where the vaccine is for prophylactic use, the human is preferably a child (*e.g.* a toddler or infant) or a teenager; where the vaccine is for therapeutic use, the human is preferably an adult. A vaccine intended for children may also be administered to adults *e.g.*

to assess safety, dosage, immunogenicity, *etc.*

The invention also provides a composition of the invention for use as a medicament. The medicament is preferably able to raise an immune response in a mammal (*i.e.* it is an immunogenic composition) and is more preferably a vaccine.

The invention also provides the use of a (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; (iv) one or more polypeptide antigens from serogroup B; and, optionally, (v) a conjugated serogroup A capsular saccharide antigen, in the manufacture of a medicament for raising an immune response in a mammal.

These uses and methods are preferably for the prevention and/or treatment of a disease caused by a *Neisseria* (*e.g.* meningitis, septicaemia, bacteremia, gonorrhoea, *etc.*). The prevention and/or treatment of bacterial and/or meningococcal meningitis is preferred.

One way of checking efficacy of therapeutic treatment involves monitoring *Neisserial* infection after administration of the composition of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses against the five basic antigens after administration of the composition. Immunogenicity of compositions of the invention can be determined by administering them to test subjects (*e.g.* children 12-16 months age, or animal models [188]) and then determining standard parameters including serum bactericidal antibodies (SBA) and ELISA titres (GMT) of total and high-avidity anti-capsule IgG. These immune responses will generally be determined around 4 weeks after administration of the composition, and compared to values determined before administration of the composition. A SBA increase of at least 4-fold or 8-fold is preferred. Where more than one dose of the composition is administered, more than one post-administration determination may be made.

Preferred compositions of the invention can confer an antibody titre in a patient that is superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects. Antigens with an associated antibody titre above which a host is considered to be seroconverted against the antigen are well known, and such titres are published by organisations such

as WHO. Preferably more than 80% of a statistically significant sample of subjects is seroconverted, more preferably more than 90%, still more preferably more than 93% and most preferably 96-100%.

Compositions of the invention will generally be administered directly to a patient. Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, aural, pulmonary or other mucosal administration. Intramuscular administration to the thigh or the upper arm is preferred. Injection may be via a needle (e.g. a hypodermic needle), but needle-free injection may alternatively be used. A typical intramuscular dose is 0.5 ml.

The invention may be used to elicit systemic and/or mucosal immunity.

Dosage treatment can be a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. A primary dose schedule may be followed by a booster dose schedule. Suitable timing between priming doses (e.g. between 4-16 weeks), and between priming and boosting, can be routinely determined.

Neisserial infections affect various areas of the body and so the compositions of the invention may be prepared in various forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. The composition may be prepared for pulmonary administration e.g. as an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration e.g. as spray, drops, gel or powder [e.g. refs 189 & 190]. Success with nasal administration of pneumococcal saccharides [191,192], pneumococcal polypeptides [193], Hib saccharides [194], MenC saccharides [195], and mixtures of Hib and MenC saccharide conjugates [196] has been reported.

#### *Storage stability*

The compositions of the invention offer improved stability, particularly for the serogroup A saccharide component. The invention provides a process for preparing a vaccine composition, comprising the steps of: (1) mixing (i) a conjugated serogroup C capsular saccharide antigen, (ii) a conjugated serogroup W135 capsular saccharide antigen, (iii) a conjugated serogroup Y capsular saccharide antigen, and (iv) one or more polypeptide antigens from serogroup B; (2) storing the composition resulting from step (1) for at least 1 week; (3) preparing a syringe containing the stored composition from step (2), ready for injection to a patient; and, optionally (4) injecting the composition into the patient.

Step (1) may also involve mixing (v) a conjugated serogroup A capsular saccharide antigen. It may also involve mixing (vi) a conjugated Hib antigen. It may also involve mixing (vii) a pneumococcal antigen. Step (2) preferably involves at least 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks or longer of storage. Storage step (2) may or may not be below room temperature (e.g. at  $10\pm 10^{\circ}\text{C}$ ).

The invention also provides a process for preparing a vaccine composition, comprising the steps of: (1) mixing (i) a conjugated serogroup C capsular saccharide antigen, (ii) a conjugated serogroup W135 capsular saccharide antigen, (iii) a conjugated serogroup Y capsular saccharide antigen, and (iv) one or more polypeptide antigens from serogroup B; and (2) extracting a unit dose volume from the mixed antigens; and (c) packaging the extracted unit dose in a hermetically-sealed container.

Step (1) may also involve mixing (v) a conjugated serogroup A capsular saccharide antigen. It may also involve mixing (vi) a conjugated Hib antigen. It may also involve mixing (vii) a pneumococcal antigen. The hermetically-sealed container may be a vial or a syringe.

The invention provides a hermetically-sealed container, containing a composition of the invention.

## 10 **General**

The term "comprising" means "including" as well as "consisting" *e.g.* a composition "comprising" X may consist exclusively of X or may include something additional *e.g.* X + Y.

The term "about" in relation to a numerical value *x* means, for example,  $x \pm 10\%$ .

The word "substantially" does not exclude "completely" *e.g.* a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

References to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of reference 197. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is taught in reference 198.

The term "alkyl" refers to alkyl groups in both straight and branched forms. The alkyl group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -NH- or -S-. The alkyl group may also be interrupted with 1, 2 or 3 double and/or triple bonds. However, the term "alkyl" usually refers to alkyl groups having no heteroatom interruptions or double or triple bond interruptions. Where reference is made to C<sub>1-12</sub> alkyl, it is meant the alkyl group may contain any number of carbon atoms between 1 and 12 (*e.g.* C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>). Similarly, where reference is made to C<sub>1-6</sub> alkyl, it is meant the alkyl group may contain any number of carbon atoms between 1 and 6 (*e.g.* C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>).

The term "cycloalkyl" includes cycloalkyl, polycycloalkyl, and cycloalkenyl groups, as well as combinations of these with alkyl groups, such as cycloalkylalkyl groups. The cycloalkyl group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -NH- or -S-. However, the term "cycloalkyl" usually refers to cycloalkyl groups having no heteroatom interruptions. Examples of cycloalkyl groups include cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexylmethyl and adamantyl

groups. Where reference is made to C<sub>3-12</sub> cycloalkyl, it is meant that the cycloalkyl group may contain any number of carbon atoms between 3 and 12 (e.g. C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>).

The term "aryl" refers to an aromatic group, such as phenyl or naphthyl. Where reference is made to C<sub>5-12</sub> aryl, it is meant that the aryl group may contain any number of carbon atoms between 5 and 12 (e.g. C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>).

The term "C<sub>5-12</sub> aryl-C<sub>1-6</sub> alkyl" refers to groups such as benzyl, phenylethyl and naphthylmethyl.

Nitrogen protecting groups include silyl groups (such as TMS, TES, TBS, TIPS), acyl derivatives (such as phthalimides, trifluoroacetamides, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl (Boc), benzyloxycarbonyl (Z or Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), 2-(trimethylsilyl)ethoxy carbonyl, 2,2,2-trichloroethoxycarbonyl (Troc)), sulfonyl derivatives (such as β-trimethylsilylethanesulfonyl (SES)), sulfenyl derivatives, C<sub>1-12</sub> alkyl, benzyl, benzhydryl, trityl, 9-phenylfluorenyl *etc.* A preferred nitrogen protecting group is Fmoc.

Sequences included to facilitate cloning or purification, *etc.*, do not necessarily contribute to the invention and may be omitted or removed.

It will be appreciated that sugar rings can exist in open and closed form and that, whilst closed forms are shown in structural formulae herein, open forms are also encompassed by the invention.

Polypeptides of the invention can be prepared by various means (e.g. recombinant expression, purification from cell culture, chemical synthesis (at least in part), *etc.*) and in various forms (e.g. native, fusions, non-glycosylated, lipidated, *etc.*). They are preferably prepared in substantially pure form (*i.e.* substantially free from other *N.meningitidis* or host cell proteins). Whilst expression of the polypeptide may take place in *Neisseria*, a heterologous host is preferred. The heterologous host may be prokaryotic (e.g. a bacterium) or eukaryotic. It is preferably *E.coli*, but other suitable hosts include *Bacillus subtilis*, *Vibrio cholerae*, *Salmonella typhi*, *Salmonella typhimurium*, *Neisseria lactamica*, *Neisseria cinerea*, *Mycobacteria* (e.g. *M.tuberculosis*), yeast, *etc.*

Nucleic acid according to the invention can be prepared in many ways (e.g. by chemical synthesis (at least in part), from genomic or cDNA libraries, from the organism itself, *etc.*) and can take various forms (e.g. single stranded, double stranded, vectors, probes, *etc.*). They are preferably prepared in substantially pure form (*i.e.* substantially free from other *N.meningitidis* or host cell nucleic acids). The term "nucleic acid" includes DNA and RNA, and also their analogues, such as those containing modified backbones (e.g. phosphorothioates, *etc.*), and also peptide nucleic acids (PNA) *etc.* The invention includes nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).

After serogroup, meningococcal classification includes serotype, serosubtype and then immunotype, and the standard nomenclature lists serogroup, serotype, serosubtype, and immunotype, each separated by a colon e.g. B:4:P1.15:L3,7,9. Within serogroup B, some lineages cause disease often (hyperinvasive), some lineages cause more severe forms of disease than others (hypervirulent), and

others rarely cause disease at all. Seven hypervirulent lineages are recognised, namely subgroups I, III and IV-1, ET-5 complex, ET-37 complex, A4 cluster and lineage 3. These have been defined by multilocus enzyme electrophoresis (MLEE), but multilocus sequence typing (MLST) has also been used to classify meningococci [ref. 83].

## 5 MODES FOR CARRYING OUT THE INVENTION

### *ΔG287-953 hybrid protein*

DNA encoding protein 287 from meningococcal serogroup B strain 394/98 and protein 953 from meningococcal serogroup B strain 2996 were digested and ligated, together with a short linker sequence, to give a plasmid encoding amino acid sequence SEQ ID 7. The plasmid was transfected into *E.coli* and bacteria were grown to express the protein. After adequate growth, bacteria were harvested and the protein was purified. From culture, bacteria were centrifuged and the pellet was homogenized in the presence of 50 mM acetate buffer (pH 5) with a pellet:buffer volume ratio of 1:8. Lysis was performed using a high pressure homogenizer (AVESTIN, 4 cycles at 14000 psi). After lysis, urea was added at final concentration of 5M, followed by agitation for 1 hour at room temperature. The pH was reduced from 6 to 5 using 200 mM acetate buffer (pH 4) + 5 M urea. The mixture was centrifuged at 16800g for 60 minutes at 2-8°C. The supernatant was collected and filtered by SARTOBRAN P (0.45-0.22μm SARTORIUS). Protein in the filtered supernatant was stable for at least 30 days at -20°C and for at least 15 days at 2-8°C.

Protein was further purified on a cationic exchange column (SPFF, Amersham Biosciences) with elution using 350mM NaCl + 50 mM acetate + 5 M urea pH 5.00. The majority of impurities were present in the flow-thru. A pre-elution washing using a lower NaCl concentration (180 mM) advantageously eliminated two contaminating *E.coli* proteins .

The eluted material was adjusted to pH 8 (using 200 mM TRIS/HCl + 5 M urea pH 9) and further purified on a Q Sepharose HP column (Amersham) with elution using 150 mM NaCl + 20 mM TRIS/HCl pH 8.00 in 5 M urea. Again, a pre-elution washing with reduced salt (90 mM) was useful for eliminating impurities.

The filtered eluted material from Q HP column was diluted 1:2 using PBS pH 7.00 (150 mM NaCl + 10 mM potassium phosphate, pH 7.00) and then diafiltered against 10 volumes of PBS pH 7.00 by tangential ultrafiltration. At the end of diafiltration the material was concentrated 1.6 times to about 1.2 mg/ml total proteins. Using a 30,000 Da cut-off membrane (Regenerated Cellulose membrane 50cm<sup>2</sup>, Millipore PLCTK 30) it was possible to dialyze the material with a yield of about 90% .

### *936-ΔG741 hybrid protein*

DNA encoding protein 936 from meningococcal serogroup B strain 2996 and protein 741 from meningococcal serogroup B strain MC58 were digested and ligated, together with a short linker sequence, to give a plasmid encoding amino acid sequence SEQ ID 8. The plasmid was transfected into *E.coli* and bacteria were grown to express the protein. The recombinant protein was not secreted, but remained soluble within the bacteria.

- After adequate growth, bacteria were centrifuged to give a humid paste and treated as follows:
- Homogenisation by high pressure system in presence of 20mM sodium phosphate pH 7.00.
  - Centrifugation and clarification by orthogonal filtration.
  - Cationic column chromatography (SP Sepharose Fast Flow), with elution by 150mM NaCl in 20mM sodium phosphate pH 7.00.
  - Anionic column chromatography (Q Sepharose XL) with flow-through harvesting.
  - Hydrophobic column chromatography (Phenyl Sepharose 6 Fast Flow High Sub) with elution by 20mM sodium phosphate, pH 7.00.
  - Diafiltration against PBS pH 7.4 with a 10Kd cut-off.
  - Final sterile filtration and storing at –20°C

Protein in the final material was stable for at least 3 months both at –20°C and at 2–8°C.

### *NadA<sup>(NL)(C)</sup> protein*

- DNA encoding NadA protein from meningococcal serogroup B strain 2996 was digested to remove the sequence encoding its C-terminus, to give a plasmid encoding amino acid sequence SEQ ID 1.
- The plasmid was transfected into *E.coli* and bacteria were grown to express the protein. The recombinant protein was secreted into the culture medium, and the leader peptide was absent in the secreted protein (SEQ ID 2). The supernatant was treated as follows:

- Concentration 7X and diafiltration against buffer 20mM TRIS/HCl pH7.6 by cross flow UF (Cut off 30Kd).
- Anionic column chromatography (Q Sepharose XL), with elution by 400mM NaCl in 20mM TRIS/HCl pH 7.6.
- Hydrophobic column chromatography step (Phenyl Sepharose 6 Fast Flow High Sub), with elution by 50mM NaCl in TRIS/HCl pH 7.6.
- Hydroxylapatite ceramic column chromatography (HA Macro. Prep) with elution by 200mM sodium phosphate pH 7.4.
- Diafiltration (cut off 30Kd) against PBS pH 7.4
- Final sterile filtration and storing at –20°C

Protein in the final material was stable for at least 6 months both at –20°C and at 2–8°C.

- NadA protein is susceptible to degradation, and truncated forms of NadA may be detected by western blot or by mass spectrometry (e.g. by MALDI-TOF) indicating up to 10kDa MW loss. Degradation products can be separated from native NadA by gel filtration (e.g. using column TSK 300SWXL, precolumn TSKSWXL, TOSOHAAS). Such filtration gives three peaks: (i) a first peak with retention time 12.637 min and apparent MW 885.036 Da; (ii) retention time 13.871 min and apparent MW 530.388 Da; (iii) retention time 13.871 min and apparent MW 530.388 Da. Light scattering analysis of the three peaks reveals real MW values of (i) 208500 Da, (ii) 98460 Da, (iii) 78760 Da. Thus the first peak contains NadA aggregates, and the third peak contains degradation products.



As the predicted molecular weight of NadA<sup>(NL)(C)</sup> is 34.113 Da, peak (ii) contains a trimeric protein, which is the desired antigen.

#### *Antigenic combinations*

Mice were immunised with a composition comprising the three proteins and, for comparison purposes, the three proteins were also tested singly. Ten mice were used per group. The mixture was able to induce high bactericidal titres against various strains:

	Meningococcal strain (Serogroup)							
	2996 <sup>(B)</sup>	MC58 <sup>(B)</sup>	NGH38	394/98 <sup>(B)</sup>	H44/76 <sup>(B)</sup>	F6124 <sup>(A)</sup>	BZ133 <sup>(C)</sup>	C11 <sup>(C)</sup>
(1)	32000	16000	130000	16000	32000	8000	16000	8000
(2)	256	131000	128	16000	32000	8000	16000	<4
(3)	32000	8000	—	—	—	8000	—	32000
Mix	32000	32000	65000	16000	260000	65000	>65000	8000

‘—’ indicates that this strain contains no NadA gene

Looking at individual mice, the triple mixture induced high and consistent bactericidal titres against the three serogroup B strains from which the individual antigens are derived:

#	1	2	3	4	5	6	7	8	9	10
2996	32768	16384	65536	32768	32768	65536	65536	32768	65536	8192
MC58	65536	32768	65536	65536	65536	8192	65536	32768	32768	65536
394/98	65536	4096	16384	4096	8192	4096	32768	16384	8192	16384

#### *Combination and comparison with OMVs*

In further experiments, the antigens (20µg of each antigen per dose) were administered in combination with 10µg OMVs prepared either from strain H44/76 (Norway) or strain 394/98 (New Zealand).

Positive controls were the anti-capsular SEAM-3 mAb for serogroup B or CRM197-conjugated capsular saccharides for other strains. The mixture almost always gave better titres than simple OMVs, and addition of the mixture to OMVs almost always significantly enhanced the efficacy of the OMVs. In many cases the antigen mixture matched or exceeded the response seen with the positive control.

#### *Hypervirulent lineage tests*

The following antigens were tested against a variety of serogroup B strains from a variety of hypervirulent lineages:

(a) NadA<sup>(NL)(C)</sup>

(b) ΔG287-953

(c) 936-ΔG741

(d) a mixture of (a), (b) and (c)

(e) OMVs prepared from strain H44/76 (Norway)

(f) OMVs prepared from strain 394/98 (New Zealand)

(g) A mixture of ΔG287 and (e)

(h) A mixture of (d) and (e)

(i) A mixture of (d) and (f)

SEAM-3 was used as a positive control.

Results were as follows, expressed as the percentage of strains in the indicated hypervirulent lineage where the serum bactericidal titre exceeded 1024:

	# strains	(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	S-3
<b>A4</b>	4	50	50	0	100	25	25	25	100	100	+
<b>ET-5</b>	8	25	75	88	100	71	14	71	100	100	+
<b>Lineage 3</b>	13	0	75	15	93	8	85	8	92	93	+
<b>ET-37</b>	4	11	22	0	33	0	0	0	22	25	+

Against particular reference strains, bactericidal titres were as follows:

	Strain	(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	S-3
<b>A4</b>	961-5945	128	2048	<8	2048	262144	8192	262144	262144	4096	8192
<b>ET-5</b>	44/76	<4	2048	32768	131072	524288	8192	524288	524288	524288	16384
<b>Lineage 3</b>	394/98	<4	1024	32	4096	<4	16384	256	16384	16384	16384
<b>ET-37</b>	LPN17592	2048	1024	256	4096	<8	<8	512	16384	65536	1024

10 Compositions (d), (h) and (i) therefore induce bactericidal antibody responses against a wide variety of strains of serogroup B meningococcus from within hypervirulent lineages A4, ET-5 and lineage 3. Titres using compositions (h) and (i) were generally higher than with (d), but the coverage of strains within hypervirulent lineages A4, ET-5 and lineage 3 were no better.

Coverage of untyped strains was also high with compositions (d), (h) and (i).

#### *Combination with meningococcal and/or Hib conjugates*

15 The triple MenB composition is combined with a mixture of oligosaccharide conjugates for serogroups C, W135 and Y, to give a vaccine containing the following antigens:


Component	Quantity per 0.5ml dose
Serogroup C conjugate	10 µg saccharide + 12.5-25 µg CRM <sub>197</sub>
Serogroup W135 conjugate	10 µg saccharide + 6.6-20 µg CRM <sub>197</sub>
Serogroup Y conjugate	10 µg saccharide + 6.6-20 µg CRM <sub>197</sub>
ΔG287-953	20 µg polypeptide
936-ΔG741	20 µg polypeptide
NadA	20 µg polypeptide

A similar vaccine is prepared, including MenA conjugate (10 µg saccharide + 12.5-33 µg CRM<sub>197</sub>) and/or a HbOC Hib conjugate (10 µg saccharide + 2-5 µg CRM<sub>197</sub>).

### Use of modified MenA saccharide

Capsular polysaccharide was purified from MenA and was hydrolysed to give MenA oligosaccharide. The polysaccharide (2 g) was hydrolyzed at 50°C in 50 mM sodium acetate buffer, pH 4.75, at a polysaccharide concentration of 10 mg/mL for about 4 hours [62]. After hydrolysis, the solution was dried by rotary evaporation.

The oligosaccharide was activated using the following reaction scheme:



The oligosaccharide was dissolved in DMSO to give a saccharide concentration of 10 mg/mL. According to a molar ratio of oligosaccharide:CDI being 1:20, 21.262 g of CDI was then added and the reaction mixture stirred for 16 hours at room temperature. The resulting MenA-CDI compound was purified by selective precipitation in a 80:20 (v/v) acetone:DMSO mixture followed by centrifugation. The efficiency of the activation reaction was calculated to be about 67.9% by determining the ratio of free imidazole to bonded imidazole.

In the second reaction step, the MenA-CDI oligosaccharide was solubilised in DMSO at a saccharide concentration of about 10 mg/mL. According to a molar ratio of MenA-CDI unit:DMA being 1:100, 36.288 g of 99% dimethylamine hydrochloride (*i.e.*  $R^1$  &  $R^2$  = Me) was added and the reaction mixture stirred for 16 hours at room temperature. The reaction product was freeze-dried and re-solubilised in 10 mg/mL water solution.

To remove the low molecular weight reaction reagent (in particular the dimethylamine (DMA)) from the oligosaccharide preparation, a dialysis step was performed through a 3.5 kDa MWCO membrane (Spectra/Por™). Four dialysis steps were carried out: (i) 16 hours against 2 L of 1 M sodium chloride (dialysis factor 1:20), (ii) 16 hours against 2 L of 0.5 M sodium chloride (dialysis factor 1:20), (iii) and (iv) 16 hours against 2 L of WFI (dialysis factor 1:20). To improve the purification a diafiltration step was also performed through a 1 kDa MWCO membrane (Centricon™).

The purified MenA-CDI-DMA product was buffered at pH 6.5 in 25 mM L-histidine (Fluka™).

For preparing conjugates of the modified MenA saccharide (MenA-CDI-DMA), the overall process was as follows:

- hydrolysis of the polysaccharide to give oligosaccharide fragments
- sizing of the oligosaccharide fragments
- reductive amination of terminal aldehyde groups on the sized oligosaccharides
- protection of terminal -NH<sub>2</sub> groups by Fmoc group before the CDI reaction
- 5    – intrinsic de-protection of -NH<sub>2</sub> groups during the DMA reaction
- activation of terminal -NH<sub>2</sub> groups by SIDEA (N-hydroxysuccinimide adipic acid)
- covalent attachment to CRM<sub>197</sub> protein

10    The modified MenA oligosaccharide conjugate was much more resistant to hydrolysis than its natural counterpart at elevated temperatures. After 28 days at 37°C, for instance, the percentage of released saccharide is 6.4% for the modified oligosaccharide vs. 23.5% for the natural antigen. Moreover, the titres induced by the modified oligosaccharides are not significantly lower than those obtained using the native sugar structures.

15    The modified MenA conjugate is combined with MenC, MenW135 and MenY conjugates as a substitute for the conjugate of unmodified oligosaccharide. This tetravalent mixture is mixed with the three MenB polypeptides to give a vaccine effective against serogroups A, B, C, W135 and Y of *N.meningitidis* in a single dose.

#### ***Pneumococcal combinations***

20    The three combined MenB proteins are mixed with pneumococcal saccharide conjugates to give a final concentration of 2µg/dose of each of the pneumococcal serotypes (double for serotype 6B). The reconstituted vaccine thus contains the following antigens:

Component	Quantity per 0.5ml dose
Serogroup A conjugate	5 µg saccharide + 6.25-16.5 µg CRM <sub>197</sub>
Serogroup C conjugate	5 µg saccharide + 6.25-12.5 µg CRM <sub>197</sub>
Serogroup W135 conjugate	5 µg saccharide + 3.3-10 µg CRM <sub>197</sub>
Serogroup Y conjugate	5 µg saccharide + 3.3-10 µg CRM <sub>197</sub>
Pneumococcus serotype 4 conjugate	2 µg saccharide + 2.5 µg CRM <sub>197</sub>
Pneumococcus serotype 9V conjugate	2 µg saccharide + 2.5 µg CRM <sub>197</sub>
Pneumococcus serotype 14 conjugate	2 µg saccharide + 2.5 µg CRM <sub>197</sub>
Pneumococcus serotype 18C conjugate	2 µg saccharide + 2.5 µg CRM <sub>197</sub>
Pneumococcus serotype 19F conjugate	2 µg saccharide + 2.5 µg CRM <sub>197</sub>
Pneumococcus serotype 23F conjugate	2 µg saccharide + 2.5 µg CRM <sub>197</sub>
Pneumococcus serotype 6B conjugate	4 µg saccharide + 5 µg CRM <sub>197</sub>

It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

## REFERENCES (the contents of which are hereby incorporated by reference)

- [1] Darkes & Plosker (2002) *Paediatr Drugs* 4:609-630.
- [2] Jones (2001) *Curr Opin Investig Drugs* 2:47-49.
- [3] Armand *et al.* (1982) *J. Biol. Stand.* 10:335-339.
- [4] Cadoz *et al.* (1985) *Vaccine* 3:340-342.
- [5] Baklaic *et al.* (1983) *Infect. Immun.* 42:599-604.
- [6] MMWR (1997) 46(RR-5) 1-10.
- [7] Bjune *et al.* (1991) *Lancet* 338(8775):1093-96
- [8] Frash (1990) p.123-145 of *Advances in Biotechnological Processes* vol. 13 (eds. Mizrahi & Van Wezel).
- [9] WO03/007985.
- [10] Inzana (1987) *Infect. Immun.* 55:1573-1579.
- [11] Kandil *et al.* (1997) *Glycoconj J* 14:13-17.
- [12] Berkin *et al.* (2002) *Chemistry* 8:4424-4433.
- [13] WO03/080678.
- [14] Nilsson & Svensson (1979) *Carbohydrate Research* 69: 292-296)
- [15] Ramsay *et al.* (2001) *Lancet* 357(9251):195-196.
- [16] Lindberg (1999) *Vaccine* 17 Suppl 2:S28-36.
- [17] Buttery & Moxon (2000) *J R Coll Physicians Lond* 34:163-168.
- [18] Ahmad & Chapnick (1999) *Infect Dis Clin North Am* 13:113-133, vii.
- [19] Goldblatt (1998) *J. Med. Microbiol.* 47:563-567.
- [20] European patent 0477508.
- [21] US patent 5,306,492.
- [22] WO98/42721.
- [23] *Conjugate Vaccines* (eds. Cruse *et al.*) ISBN 3805549326, particularly vol. 10:48-114.
- [24] Hermanson (1996) *Bioconjugate Techniques* ISBN: 0123423368 or 012342335X.
- [25] Anonymous (Jan 2002) *Research Disclosure*, 453077.
- [26] Anderson (1983) *Infect Immun* 39(1):233-238.
- [27] Anderson *et al.* (1985) *J Clin Invest* 76(1):52-59.
- [28] EP-A-0372501.
- [29] EP-A-0378881.
- [30] EP-A-0427347.
- [31] WO93/17712
- [32] WO94/03208.
- [33] WO98/58668.
- [34] EP-A-0471177.
- [35] WO91/01146
- [36] Falugi *et al.* (2001) *Eur J Immunol* 31:3816-3824.
- [37] EP-A-0594610.
- [38] WO00/56360.
- [39] WO02/091998.
- [40] WO01/72337
- [41] WO00/61761.
- [42] WO99/42130
- [43] WO96/40242
- [44] Lees *et al.* (1996) *Vaccine* 14:190-198.
- [45] WO95/08348.
- [46] US patent 4,882,317
- [47] US patent 4,695,624

- [48] Porro *et al.* (1985) *Mol Immunol* 22:907-919.
- [49] EP-A-0208375
- [50] WO00/10599
- [51] Gever *et al.* *Med. Microbiol. Immunol*, 165 : 171-288 (1979).
- [52] US patent 4,057,685.
- [53] US patents 4,673,574; 4,761,283; 4,808,700.
- [54] US patent 4,459,286.
- [55] US patent 4,965,338
- [56] US patent 4,663,160.
- [57] US patent 4,761,283
- [58] US patent 4,356,170
- [59] Lei *et al.* (2000) *Dev Biol (Basel)* 103:259-264.
- [60] WO00/38711; US patent 6,146,902.
- [61] Ravenscroft *et al.* (1999) *Vaccine* 17:2802-2816.
- [62] Costantino *et al.* (1999) *Vaccine* 17:1251-1263.
- [63] Parkhill *et al.* (2000) *Nature* 404:502-506.
- [64] Tettelin *et al.* (2000) *Science* 287:1809-1815.
- [65] WO00/66791.
- [66] Pizza *et al.* (2000) *Science* 287:1816-1820.
- [67] WO99/24578.
- [68] WO99/36544.
- [69] WO99/57280.
- [70] WO00/22430.
- [71] WO00/66741.
- [72] WO01/64920.
- [73] WO01/64922.
- [74] WO03/020756.
- [75] UK patent applications 0223741.0, 0305831.0 & 0309115.4, and international patent application PCT/IB03/\_\_\_\_\_ filed on 2 October 2003 claiming priority from these three UK patent applications.
- [76] Comanducci *et al.* (2002) *J. Exp. Med.* 195:1445-1454.
- [77] WO03/010194.
- [78] UK patent application 0227346.4.
- [79] WO03/063766.
- [80] Masignani *et al.* (2003) *J Exp Med* 197:789-799.
- [81] <http://neisseria.org/nm/typing/mlst/>
- [82] Pettersson *et al.* (1994) *Microb Pathog* 17(6):395-408.
- [83] Maiden *et al.* (1998) *PNAS USA* 95:3140-3145.
- [84] Welsch *et al.* (2002) Thirteenth International Pathogenic Neisseria Conference, Norwegian Institute of Public Health, Oslo, Norway; Sept. 1-6, 2002. *Genome-derived antigen (GNA) 2132 elicits protective serum antibodies to groups B and C Neisseria meningitidis strains.*
- [85] Santos *et al.* (2002) Thirteenth International Pathogenic Neisseria Conference, Norwegian Institute of Public Health, Oslo, Norway; Sept. 1-6, 2002. *Serum bactericidal responses in rhesus macaques immunized with novel vaccines containing recombinant proteins derived from the genome of N. meningitidis.*
- [86] WO96/14086.
- [87] *Vaccines* (eds. Plotkin & Mortimer), 1988. ISBN: 0-7216-1946-0
- [88] Gustafsson *et al.* (1996) *N. Engl. J. Med.* 334:349-355.
- [89] Rappuoli *et al.* (1991) *TIBTECH* 9:232-238.
- [90] Bell (2000) *Pediatr Infect Dis J* 19:1187-1188.

- [91] Iwarson (1995) *APMIS* 103:321-326.
- [92] Gerlich *et al.* (1990) *Vaccine* 8 Suppl:S63-68 & 79-80.
- [93] WO93/24148.
- [94] Sutter *et al.* (2000) *Pediatr Clin North Am* 47:287-308.
- [95] Zimmerman & Spann (1999) *Am Fam Physician* 59:113-118, 125-126.
- [96] Charalambous & Feavers (2001) *J Med Microbiol* 50:937-939.
- [97] Westerink (2001) *Int Rev Immunol* 20:251-261.
- [98] Grothaus *et al.* (2000) *Vaccine* 18:1253-1263.
- [99] Kanra *et al.* (1999) *The Turkish Journal of Paediatrics* 42:421-427.
- [100] Ravenscroft *et al.* (2000) *Dev Biol (Basel)* 103: 35-47.
- [101] WO97/00697.
- [102] WO02/00249.
- [103] WO96/37222; US patent 6,333,036.
- [104] Watson (2000) *Pediatr Infect Dis J* 19:331-332.
- [105] Rubin (2000) *Pediatr Clin North Am* 47:269-285, v.
- [106] Jedrzejewski (2001) *Microbiol Mol Biol Rev* 65:187-207.
- [107] Zielen *et al.* (2000) *Infect. Immun.* 68:1435-1440.
- [108] Tettelin *et al.* (2001) *Science* 293:498-506.
- [109] Hoskins *et al.* (2001) *J Bacteriol* 183:5709-5717.
- [110] Rappuoli (2000) *Curr Opin Microbiol* 3:445-450
- [111] Rappuoli (2001) *Vaccine* 19:2688-2691.
- [112] Masignani *et al.* (2002) *Expert Opin Biol Ther* 2:895-905.
- [113] Mora *et al.* (2003) *Drug Discov Today* 8:459-464.
- [114] Wizemann *et al.* (2001) *Infect Immun* 69:1593-1598.
- [115] Rigden *et al.* (2003) *Crit Rev Biochem Mol Biol* 38:143-168.
- [116] WO02/22167.
- [117] Paoletti *et al.* (2001) *Vaccine* 19:2118-2126.
- [118] WO00/56365.
- [119] Gennaro (2000) *Remington: The Science and Practice of Pharmacy*. 20th edition, ISBN: 0683306472.
- [120] WO03/009869.
- [121] *Vaccine Design...* (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.
- [122] WO00/23105.
- [123] WO90/14837.
- [124] US patent 5,057,540.
- [125] WO96/33739.
- [126] EP-A-0109942.
- [127] WO96/11711.
- [128] WO00/07621.
- [129] Barr *et al.* (1998) *Advanced Drug Delivery Reviews* 32:247-271.
- [130] Sjolanderet *et al.* (1998) *Advanced Drug Delivery Reviews* 32:321-338.
- [131] Niikura *et al.* (2002) *Virology* 293:273-280.
- [132] Lenz *et al.* (2001) *J Immunol* 166:5346-5355.
- [133] Pinto *et al.* (2003) *J Infect Dis* 188:327-338.
- [134] Gerber *et al.* (2001) *Virol* 75:4752-4760.
- [135] WO03/024480
- [136] WO03/024481
- [137] Gluck *et al.* (2002) *Vaccine* 20:B10-B16.

- [138] EP-A-0689454.
- [139] Johnson *et al.* (1999) *Bioorg Med Chem Lett* 9:2273-2278.
- [140] Evans *et al.* (2003) *Expert Rev Vaccines* 2:219-229.
- [141] Meraldi *et al.* (2003) *Vaccine* 21:2485-2491.
- [142] Pajak *et al.* (2003) *Vaccine* 21:836-842.
- [143] Kandimalla *et al.* (2003) *Nucleic Acids Research* 31:2393-2400.
- [144] WO02/26757.
- [145] WO99/62923.
- [146] Krieg (2003) *Nature Medicine* 9:831-835.
- [147] McCluskie *et al.* (2002) *FEMS Immunology and Medical Microbiology* 32:179-185.
- [148] WO98/40100.
- [149] US patent 6,207,646.
- [150] US patent 6,239,116.
- [151] US patent 6,429,199.
- [152] Kandimalla *et al.* (2003) *Biochemical Society Transactions* 31 (part 3):654-658.
- [153] Blackwell *et al.* (2003) *J Immunol* 170:4061-4068.
- [154] Krieg (2002) *Trends Immunol* 23:64-65.
- [155] WO01/95935.
- [156] Kandimalla *et al.* (2003) *BBRC* 306:948-953.
- [157] Bhagat *et al.* (2003) *BBRC* 300:853-861.
- [158] WO03/035836.
- [159] WO95/17211.
- [160] WO98/42375.
- [161] Beignon *et al.* (2002) *Infect Immun* 70:3012-3019.
- [162] Pizza *et al.* (2001) *Vaccine* 19:2534-2541.
- [163] Pizza *et al.* (2000) *Int J Med Microbiol* 290:455-461.
- [164] Scharton-Kersten *et al.* (2000) *Infect Immun* 68:5306-5313.
- [165] Ryan *et al.* (1999) *Infect Immun* 67:6270-6280.
- [166] Partidos *et al.* (1999) *Immunol Lett* 67:209-216.
- [167] Peppoloni *et al.* (2003) *Expert Rev Vaccines* 2:285-293.
- [168] Pine *et al.* (2002) *J Control Release* 85:263-270.
- [169] Domenighini *et al.* (1995) *Mol Microbiol* 15:1165-1167.
- [170] WO99/40936.
- [171] WO99/44636.
- [172] Singh *et al.* (2001) *J Cont Release* 70:267-276.
- [173] WO99/27960.
- [174] US patent 6,090,406
- [175] US patent 5,916,588
- [176] EP-A-0626169.
- [177] WO99/52549.
- [178] WO01/21207.
- [179] WO01/21152.
- [180] Andrianov *et al.* (1998) *Biomaterials* 19:109-115.
- [181] Payne *et al.* (1998) *Adv Drug Delivery Review* 31:185-196.
- [182] Stanley (2002) *Clin Exp Dermatol* 27:571-577.
- [183] Jones (2003) *Curr Opin Investig Drugs* 4:214-218.
- [184] WO99/11241.
- [185] WO94/00153.



- [186] WO98/57659.
- [187] European patent applications 0835318, 0735898 and 0761231.
- [188] WO01/30390.
- [189] Almeida & Alpar (1996) *J. Drug Targeting* 3:455-467.
- [190] Agarwal & Mishra (1999) *Indian J Exp Biol* 37:6-16.
- [191] WO00/53221.
- [192] Jakobsen *et al.* (2002) *Infect Immun* 70:1443-1452.
- [193] Wu *et al.* (1997) *J Infect Dis* 175:839-846.
- [194] Bergquist *et al.* (1998) *APMIS* 106:800-806.
- [195] Baudner *et al.* (2002) *Infect Immun* 70:4785-4790.
- [196] Ugozzoli *et al.* (2002) *J Infect Dis* 186:1358-1361.
- [197] *Current Protocols in Molecular Biology* (F.M. Ausubel *et al.*, eds., 1987) Supplement 30.
- [198] Smith & Waterman (1981) *Adv. Appl. Math.* 2: 482-489.

## CLAIMS

1. An aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is bactericidal against serogroups B, C, W135 and Y of *N.meningitidis*, wherein the composition comprises: (i) a conjugated serogroup C capsular saccharide antigen;  
5 (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; and (iv) one or more polypeptide antigens from serogroup B.
2. The composition of claim 1, further comprising: (v) a conjugated serogroup A capsular saccharide antigen.
3. The composition of claim 2, wherein the serogroup A capsular saccharide is modified such that at  
10 least 20% of its monosaccharide units do not have -OH at either of the 3 and 4 positions.
4. The composition of claim 2 or claim 3, wherein the composition can be stored for 28 days at 37°C and, after that period, less than 20% of the initial total amount of conjugated MenA saccharide will be unconjugated.
5. The composition of any preceding claim, wherein the conjugated saccharides are  
15 oligosaccharides.
6. The composition of any preceding claim, wherein the saccharides are conjugated to a carrier protein selected from: diphtheria toxoid, tetanus toxoid, *H.influenzae* protein D, and CRM<sub>197</sub>.
7. The composition of any preceding claim, wherein the composition further comprises from 1 to 10 defined serogroup B polypeptide antigens, and wherein the composition can induce an immune  
20 response that is bactericidal against two three of hypervirulent lineages A4, ET 5 and lineage 3 of *N.meningitidis* serogroup B.
8. The composition of claim 7, comprising one or more of the following five antigens: (i) a 'NadA' protein in oligomeric form; (ii) a '741' protein; (iii) a '936' protein; (iv) a '953' protein; and (v) a '287' protein.
- 25 9. The composition of claim 8, comprising: a first polypeptide comprising amino acid sequence SEQ ID NO:2; a second polypeptide comprising amino acid sequence SEQ ID NO:7; and a third polypeptide comprising amino acid sequence SEQ ID NO:8;
10. The composition of any preceding claim, further comprising a saccharide antigen that protects against *H.influenzae* type B (Hib).
- 30 11. The composition of any preceding claim, further comprising an antigen that protects against *Streptococcus pneumoniae*.
12. The composition of any preceding claim, comprising an aluminium phosphate adjuvant.
13. The composition of any preceding claim, packaged in a hermetically-sealed container.

14. The composition of claim 13, wherein the container is a vial or a syringe.

15. The composition of any preceding claim, for use as a medicament.

16. The use of a (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; (iv) one or more polypeptide antigens from serogroup B; and, optionally, (v) a conjugated serogroup A capsular saccharide antigen, in the manufacture of a medicament for raising an immune response in a mammal.

17. A method for raising an antibody response in a mammal, comprising administering a composition of any one of claims 1 to 15 to the mammal.

## SEQUENCE LISTING

### *SEQ ID 1 – NadA from strain 2996, with C-terminus deletion*

5 MKHFPSKVLTTAILATFCSGALAAATNDDDVKKAATVAIAAAYNNGQEINGFKAGETIYDIDEDGTITKKDATAADVEADDF  
KGLGLKKVVTNLTKTVNENKQNVDAKVKAASEIEKLTTKLADTDAALADTDAALDATTNALNKLGENITTFAEETKTNIV  
KIDEKLEAVADTVDKHAEAFNDIADSLDETNTKADEAVKTANEAKQTAEETKQNVDAKVKAETAAGKAEAAAGTANTAAD  
KAEAVAAKVTDIKADIATNKDNI AKKANSADVTTREESDSKFVRIDGLNATTEKLDTRLASA EKSIADHDTRLNGLDKTVS  
DLRKETRQGLAEQAALSGLFQPYNVG

### *SEQ ID 2 – NadA from strain 2996, with C-terminus deletion and leader peptide processed*

10 ATNDDDVKKAATVAIAAAYNNGQEINGFKAGETIYDIDEDGTITKKDATAADVEADDFKGLGLKKVVTNLTKTVNENKQNV  
DAKVKAASEIEKLTTKLADTDAALADTDAALDATTNALNKLGENITTFAEETKTNIVKIDEKLEAVADTVDKHAEAFNDI  
ADSLDETNTKADEAVKTANEAKQTAEETKQNVDAKVKAETAAGKAEAAAGTANTAADKAEAVAAKVTDIKADIATNKDNI  
AKKANSADVTTREESDSKFVRIDGLNATTEKLDTRLASA EKSIADHDTRLNGLDKTVSDLRKETRQGLAEQAALSGLFQPY  
NVG

### *SEQ ID 3 – AG741 from MC58 strain*

15 VAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQGAEKTYGNGDSLNTGKLKNDKVS RFD FIRQIEVDGQL  
ITLESGEFQVYKQSHSALTA FQTEQIQDSEHSGKMVAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDAGGKLTYYT  
IDFAAQQNGKIEHLKSPELNVDLAAADIKPDGKRHAVISGSVLYNQA EKGSYSLGIFGGKAQEVAGSAEVKTVNGIRHIG  
LAAKQ

### *SEQ ID 4 – 936 from MC58 strain with leader peptide processed*

20 VSAVIGSAAVGA KSAVD RRTTGAQTDDNVMALRIETTARSYLRQNNQTKGYTPQISVVGYNRHLLLLGQVATEGEKQFVGQ  
IARSEQAAEGVYNYITVASLPRTAGDIAGDTWNTSKVRATLLGISPATQARVKIVTYGNVTYVMGILTPEEQAQITQKVST  
TVGVQKVITLYQNYVQR

### *SEQ ID 5 – 953 from MC58 strain with leader peptide processed*

25 ATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQAKRDGKIDITIPIANLQSGSQHFTHDLKSADIFDAAQYPDIR  
FVSTKFNFNKGKLVSDGNLTMHGKTAPVKLKA EKFN CYQSPMEKTEVCGGDFSTTIDRTKWGMDYLVNVGMTKSVRIDIQ  
IEAAKQ

### *SEQ ID 6 – AG287 from MC58 strain*

30 SPDVKSADTL SKPAAPV VSEKETEAKEDAPQAGSQGQAPS AQGSQDMAAVSEENTGNGGAVTADNPKNEDEVAQN DMPQN  
AAGTDSSTPNHTPDNMLAGNMENQATDAGESSQPANQPD MANAADGMQGD DP SAGGQ NAGNTAAQGANQAGNNQAAGSSD  
PIPASNPAPANGGSNFRVLDLANGVLIDGPSQNI TLTHCKGDSCSGNNFLDEEVQLKSEFEKLSDADKISNYKKDGKNDKF  
VGLVADSVQMGKINQYII FYKPKPTS FARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHS GNI FAPEGNYRYL  
TYGA EKLP GGSYALRVQGEPAKGEMLAGAAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGSKSV DGIIDSGDDLHMGTOKF  
KAAIDGNGFKGTWTENGSGDVSGKFYGPAGEEVAGKYSYRPTDAEKGGFGVFAGKKEQD

### *SEQ ID 7 – 287-953 hybrid*

35 MASPDVKSADTL SKPAAPV VSEKETEAKEDAPQAGSQGQAPS AQGGQDMAAVSEENTGNGGAAATDKPKNEDEGAQN DMP  
QNAADTDSLTPNHTPASNMPAGNMENQAPDAGESEQPANQPD MANTADGMQGD DP SAGGENAGNTAAQGTNQAENNTAGS  
QNPASSTNPSATNSGGDFGR TNVGN SVVIDGPSQNI TLTHCKGDSCSGNNFLDEEVQLKSEFEKLSDADKISNYKKDGKND  
GKNDKFVGLVADSVQMGKINQYII FYKPKPTS FARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHS GNI FAPE  
GNRYRYLTYGA EKLP GGSYALRVQGEPSKGEMLAGTAVYNGEVLHFHTENGRPSPSRGRFAAKVDFGSKSV DGIIDSGDGLH  
40 MGTQKFKA AIDGNGFKGTWTENGG DVSGKFYGPAGEEVAGKYSYRPTDAEKGGFGVFAGKKEQD GSGGGGATYKVDEYHA  
NARFAIDHFNTSTNVGGFYGLTGSVEFDQAKRDGKIDITIPIANLQSGSQHFTHDLKSADIFDAAQYPDIRFVSTKFNFN  
KKLVSDGNLTMHGKTAPVKLKA EKFN CYQSPMAKTEVCGGDFSTTIDRTKWGV DYLVNVGMTKSVRIDIQIEAAKQ\*

### *SEQ ID 8 – 936-741 hybrid*

45 MVS AVIGSAAVGA KSAVD RRTTGAQTDDNVMALRIETTARSYLRQNNQTKGYTPQISVVGYNRHLLLLGQVATEGEKQFVG  
QIARSEQAAEGVYNYITVASLPRTAGDIAGDTWNTSKVRATLLGISPATQARVKIVTYGNVTYVMGILTPEEQAQITQKVS

TTVGQVKVITLYQNYVQRSGGGGVAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQAEKTYGNGDSLNTGKLKNDKVSRLFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQDSEHSGKMAKQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDAGGKLTYYTIDFAAQQNGKIEHLKSPELNVDLAAADIKPDGKRHAVISGSVLYNQAEGKSYSLGIFGGKAQEVAGSAEVKTVNGIRHIGLAAKQ\*

5 **SEQ ID 9 – linker**

---

GSGGGG

**SEQ ID 10 – 741 sequence**

---

10 CSSGGGGVAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQAEKTYGNGDSLNTGKLKNDKVSRLFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQDSEHSGKMAKQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDAGGKLTYYTIDFAAQQNGKIEHLKSPELNVDLAAADIKPDGKRHAVISGSVLYNQAEGKSYSLGIFGGKAQEVAGSAEVKTVNGIRHIGLAAKQ

**SEQ ID 11 – 741 sequence**

---

15 CSSGGGGVAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLKLAQAQAEKTYGNGDSLNTGKLKNDKVSRLFDFIRQIEVDGQLITLESGEFQIYKQDHSVALQIEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPDGKAEYHGKAFSSDDAGGKLTYYTIDFAAQQGHGKIEHLKTPEQNVELAAELKADEKSHAVILGDTRYGSEEKGTYHLALFGDRAQEIAGSATVKIGEKVHEIGIAGKQ

**SEQ ID 12 – 741 sequence**

---

20 CSSGGGGSGGGGVAADIGTGLADALTAPLDHKDKGLKSLTLED SIPQNGTLTSLAQAQAEKTFKAGDKDNSLNTGKLKNDKISRFDVQKIEVDGQTITLASGEFQIYKQNHSAVVALQIEKINNPDKIDSLINQRSFLVSGLGGEHTAFNQLPGGKAEYHGKAFSSDDPNGLHYSIDFTKKQGYGRIEHLKTLEQNVELAAELKADEKSHAVILGDTRYGSEEKGTYHLALFGDRAQEIAGSATVKIGEKVHEIGIAGKQ